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ABSTRACT
The Mixed Lineage Leukemia (MLL) gene can participate in chromosomal
translocations which generate a fusion protein leading to aggressive, acute leukemia.
These translocations may occur spontaneously or following previous treatments with
particular chemotherapy agents. Compared to other types of acute leukemia, MLLassociated leukemias have a poor prognosis. A better understanding of how MLL fusion
proteins contribute to leukemia is necessary in order to develop more effective
treatments.
MLL fusion proteins retain the amino-terminal portion of MLL including the
CXXC DNA-binding domain while the carboxy-terminal portion of the oncoprotein is
comprised of the fusion partner. The MLL CXXC domain is a zinc-coordinating
structure which binds to non-methylated DNA within the promoter region of target genes.
The CXXC domain is located within a functional repression domain which is known to
interact with cofactor proteins that modulate target gene expression. In my dissertation
project, I investigated the functional role of amino acids within the CXXC domain to
determine how specific residues contribute to the leukemogenic capacity of MLL fusion
proteins.
The closest homolog of MLL, MLL2 (alternatively named MLL4), also contains a
similar CXXC domain, yet an artificial MLL2 fusion protein is unable to transform cells
in vitro. Knowing that the CXXC domain is a critical component of MLL fusion
xii

proteins, I hypothesized that specific amino acid differences between MLL and MLL2
CXXC domains account for differences in leukemogenic capacity. To test this
hypothesis, the MLL2 CXXC domain was cloned into the context of the well-studied
MLL-AF9 fusion protein to generate an artificial MLL/MLL2-AF9 chimera. Amino acid
substitutions within the MLL2 CXXC domain were then introduced to restore residues to
the MLL amino acid sequence within this synthetic chimera. Retroviral transduction of
bone marrow progenitor cells with the wild type or mutant chimeric MLL/MLL2-AF9
fusions was performed to measure proliferation capacity in a methylcellulose colony
assay. Colony forming ability and cell proliferation were then measured along with
observations in cellular morphology and target gene expression to determine the
functional contributions of specific residues within the CXXC domain of the fusion
proteins. In vitro binding studies were performed between MLL or synthetic
MLL/MLL2 repression domain protein fragments and cofactor proteins to determine if
there were differences in protein interactions which could account for the observed
functional differences. By comparing the residues of the MLL and MLL2 CXXC
domains, critical amino acids were identified on both the DNA-binding surface and on
the opposite, non-DNA-contact surface of the CXXC domain that contribute to
leukemogenic transformation.
Cysteine 1188 of the MLL CXXC domain is the only non-zinc-coordinating
cysteine residue within the CXXC domain. This residue is critically positioned on the
DNA-binding surface, and our laboratory has previously shown that mutation of this
residue can disrupt the ability of the CXXC domain to bind to DNA. With a critical
location on the DNA-binding surface and potential susceptibility to post-translational
xiii

modification, I hypothesized that the side chain of Cys1188 may be physiologically
altered to regulate DNA-binding affinity. Transformed MLL-AF9 progenitor cells were
treated with modifying agents or grown under conditions of varying oxygen
concentration, and cell viability and colony forming ability were measured. The MLLAF9 cells showed a modest increase in susceptibility to parthenolide treatment in an in
vitro colony assay compared to control cells suggesting that Cys1188 may be altered
through redox regulation. Growth under conditions of varying oxygen levels, however,
showed no significant differences in proliferation of wild type or control cells. These
results build on the initial studies of Cys1188 and the MLL CXXC domain conducted in
our lab and provide valuable direction for future investigations which may eventually
allow for therapeutic targeting of the CXXC domain in these aggressive forms of MLLassociated leukemia.
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CHAPTER 1
INTRODUCTION
The Mixed Lineage Leukemia (MLL) gene is involved in translocations with more
than 60 possible fusion partners leading to aggressive, acute leukemias with poor
prognosis. The resulting chimeric fusion protein retains the N-terminal portion of MLL
including the CXXC DNA-binding domain, while the C-terminal portion of the
oncoprotein is comprised of the fusion partner1, 2. The CXXC domain is found within a
functionally-defined repression domain and binds to non-methylated CpG DNA3-5. This
CXXC DNA-binding domain contains a clustering of eight cysteines which coordinate
two zinc ions and is essential for the transformation capacity of cells expressing an MLL
fusion protein4. The closest homolog of MLL, MLL2 (alternatively named MLL4), also
contains a similar CXXC domain which preferentially binds non-methylated CpG DNA
but with lower affinity than the MLL CXXC domain (Bushweller laboratory, University
of Virginia, unpublished)6, 7. Interestingly, cells expressing an artificial MLL2 fusion
protein do not transform primary bone marrow cells and require the substitution of the
MLL CXXC domain plus the ‘post-CXXC’ residues—a region comprising the majority
of the MLL repression domain—in order to become immortalized in vitro7. I
hypothesized that amino acid differences between the CXXC domain or the repression
domain of MLL and MLL2 must contribute to these functional differences. Specific
amino acids along the DNA contact interface may play a role in differential DNA1
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binding affinity. In addition, our lab has previously shown that the repression domain of
MLL (containing the CXXC domain) binds to class I histone deacetylases (HDACs 1 and
2), polycomb group proteins (HPC2 and BMI-1), and the co-repressor C-terminal-binding
protein (CtBP)8. Recently, a co-activator protein, PAF1, was also shown to bind to this
same region of MLL9, 10. Differential binding of these cofactor proteins to MLL and
MLL2 may affect overall function but might also contribute to CXXC DNA-binding
affinity. Cysteine 1188, the only non-zinc-coordinating cysteine residue within the
CXXC domain, is critically positioned on the DNA-binding surface and adjacent to one
of the conserved cysteines involved in zinc coordination11. Previous studies conducted in
our lab showed that mutation of Cys1188 to aspartate completely abrogated the ability of
the CXXC domain to bind DNA and prevented both in vitro immortalization and
development of leukemia in mice when introduced in the context of a MLL fusion
protein11. In contrast, mutation of Cys1188 to alanine retained MLL’s ability to bind
CpG DNA, as well as to immortalize in vitro and in vivo in the context of the fusion
protein11. With a critical location on the DNA-binding surface of the CXXC domain and
susceptibility to redox regulation, I hypothesized that the side chain of Cys1188 may be
physiologically altered to regulate DNA-binding affinity, allowing this residue to
function as a molecular switch that regulates the binding of MLL to its non-methylated
CpG DNA targets.
Hypothesis: Specific amino acid residues of the MLL and MLL2 CXXC domains
function to alter DNA binding, cofactor binding, and susceptibility to post-translational
modification—critical features of MLL that determine leukemogenic capacity.
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Aim 1: Determine how differences in the MLL CXXC domain and the MLL2 CXXC
domain contribute to the different transformation capacities of MLL/MLL2AF9 fusion proteins.
MLL and MLL2 are paralogs with high sequence homology. Both proteins
contain similar functional domains including the CXXC DNA-binding domain with eight
conserved Zn-coordinating cysteine residues. With such similarity, it is intriguing that
MLL2 is unable to compensate for the embryonic lethality observed in Mll -/- mice12.
Moreover, MLL2 has not been associated with translocations causing leukemia like MLL.
The CXXC domain and the ‘post-CXXC’ residues of the larger repression domain
(residues 1149-1337 of MLL) have been shown to account for the differences in
leukemogenic capabilities of these proteins7. However, the specific amino acid residues
within the repression domain which account for this difference have not yet been
identified. The repression domain of MLL has previously been shown to bind to cofactor
proteins but it is not currently known if these same co-repressors bind to MLL28-10. I
hypothesized that specific amino acid differences between MLL and MLL2 contribute to
variable DNA-binding affinities of the CXXC domains and to variable recruitment of
cofactor proteins which regulate transcription of MLL/MLL2 target genes. The first aim
of my dissertation proposed to explore how these specific amino acid differences affect
the critical functioning of the CXXC domain and alter the leukemogenic capacity of these
translocations.
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Aim 2: Determine the role of Cysteine 1188 in the regulation of the MLL CXXC
domain binding to non-methylated CpG DNA.
Cysteine 1188 of the MLL CXXC domain is the only non-zinc-coordinating
cysteine residue within the CXXC domain and is highly conserved across vertebrate
orthologs of MLL. Our lab showed that this residue is critically positioned on the DNAbinding surface and adjacent to one of the conserved cysteines involved in zinc
coordination11. Mutation of Cys1188 to aspartate completely abrogated the ability of the
CXXC domain to bind DNA even though it is not involved in direct interactions with
DNA11. Zinc finger motifs containing a zinc ion tetrahedrally coordinated to cysteine or
histidine groups are relatively common within DNA-binding proteins and can be subject
to redox regulation at free cysteine residues to alter protein function13. The hypoxic
niche (in which hematopoiesis takes place and leukemia stem cells can reside) may
protect Cys1188 of the MLL CXXC domain from oxidation. With a critical location on
the DNA-binding surface of this domain and susceptibility to post-translational
modification, I hypothesized that the side chain of Cys1188 may be physiologically
altered to regulate DNA-binding affinity, allowing this residue to function as a molecular
switch that regulates the binding of MLL to its non-methylated CpG DNA targets.
It is not well understood how the balance of gene activation and repression is
functionally regulated during normal hematopoiesis or MLL-associated leukemia. The
CXXC DNA-binding domain and the ‘post-CXXC’ residues of the MLL repression
domain have been shown to be essential for the transformation capacity of MLL fusion
proteins2, 7, 11. By studying specific amino acid residues of the MLL CXXC domain, the
goal of my dissertation was to better understand functional features that contribute to
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MLL’s ability to bind to DNA and to cofactor proteins and the potential post-translational
modifications which we hypothesized are critical determination features for MLLassociated leukemia. My work serves as a starting point for therapeutic targeting of the
MLL CXXC domain to alter leukemogenic capacity and, ultimately, lead to better
clinical outcomes for these devastating forms of acute leukemia.

CHAPTER 2
LITERATURE REVIEW
The Mixed Lineage Leukemia (MLL) gene and leukemia
The Mixed Lineage Leukemia (MLL) gene was first identified for its involvement
in translocations at the 11q23 locus associated with acute leukemia14. The MLL gene
(also called MLL1, HRX, HTRX, or ALL-1) derives its name from the clinical presentation
associated with its cytogenetic aberration: patients with these chromosomal
rearrangements develop the pathological phenotype of acute lymphoid leukemia (ALL),
acute myeloid leukemia (AML), or a mixed lineage leukemia15-18. MLL genetic
abnormalities account for 5-10% of ALL or AML cases19, 20. The incidence of MLLassociated leukemia is significantly higher, though, in two distinct populations of
leukemia cases: de novo infant leukemias and secondary leukemias which develop
following chemotherapy with high doses of DNA topoisomerase II inhibitors21, 22.
Furthermore, MLL leukemias are particularly aggressive compared to other types of
leukemia and are associated with relatively dismal outcomes with five-year survival rates
of only 20-30% in infants20, 23-25.
The most common genetic abnormality associated with the MLL gene is an inframe, chromosomal translocation which results in a chimeric protein expressing the
amino-terminal end of the MLL protein fused to the carboxy-terminus of a partner
protein26-28. To date, over sixty different fusion partners have been identified in MLL
6
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leukemia cases . The type of MLL-associated leukemia that develops depends in part on
28

the particular fusion partner involved in the MLL oncoprotein. Table 1 shows the
incidence of the most common fusion partners and the associated leukemia phenotype.
Internal duplication of various exons of MLL can also lead to the development of
leukemia29-31. In these instances, a separate partner protein is not fused to the
oncoprotein; instead, specific functional domains of the MLL protein, including the
CXXC domain, are duplicated to alter normal function. These genetic aberrations of the
MLL gene disrupt normal hematopoiesis causing the bone marrow to become
overwhelmed with the production of immature leukemic cells. These rapidly
proliferating cells crowd out the production of normal blood cells leading to anemia,
bleeding disorders, and potentially to an increased susceptibility to infection. Eventually,
this uncontrolled production of undifferentiated blast cells develops into end-organ
failure and, ultimately, death in patients if the aggressive leukemia is not effectively
treated.

ALL21,28,32

AML26,28,32-33

Table 1. Occurrence of common genetic abnormalities involving MLL.
Genetic Alteration
Resultant Oncoprotein
Incidence
t(9;11)(p22;q23) MLL-AF9/MLLT3
36%
t(10;11)(p12q23) MLL-AF10/MLLT10
13%
(amplification
of
internal
domains
within
MLL)
PTD
10%
t(6;11)(q27;q23) MLL-AF6/MLLT4
9%
t(11;19)(q23;p13.1) MLL-ELL
8%
t(11;19)(q23;p13.3) MLL-ENL/MLLT1
8%
Other i.e. MLL-AF1q/MLLT11, MLL-AF17/MLLT6
15%
t(4;11)(q21;q23) MLL-AF4/AFF1
56%
t(11;19)(q23;p13.3) MLL-ENL/MLLT1
16%
t(9;11)(p22;q23) MLL-AF9/MLLT3
10%
t(10;11)(p12q23) MLL-AF10/MLLT10
3%
(amplification
of
internal
domains
within
MLL)
PTD
< 1%
Other i.e. MLL-AF6/MLLT4, MLL-EPS15/AF1P
15%
PTD: Partial Tandem Duplication
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Hematopoiesis
MLL is involved in the normal process of hematopoiesis through the regulation of
specific target genes (i.e. Hox cluster genes discussed later) which can also give rise to
forms of acute leukemia when the expression of these target genes becomes misregulated.
Hematopoiesis is the process by which the mature cells of the blood system develop from
a series of immature, precursor cells (Figure 1). The hematopoietic stem cell (HSC) is
the precursor cell from which all subsequent hematopoietic cells originate. HSCs are
distinguished by the unique properties of all adult stem cells: long-term self-renewal
which allows for the lifelong repopulation of the blood cells and pluripotency which
enables HSCs to give rise to all cell types of the blood system including myeloid,
lymphoid, and erythroid/megakaryocyte lineages. HSCs are identified by the presence or
absence of specific cell surface markers (for mouse: c-kit+, Sca1+, Lin-, Flk2-, CD34-, and
Slamf1+; and for human: CD34+, Lin-, CD38-, CD90+, and CD45RA-)34.
When stimulated to divide, an HSC can undergo asymmetrical division resulting
in two different cell types: one cell exhibiting the characteristics of an HSC that
maintains the existing HSC pool and one daughter cell that can undergo maturation into a
multipotent HSC with limited short-term repopulating capacity. This short-term HSC
then gives rise to common erythroid, myeloid, and/or lymphoid progenitor cells that
express a unique set of cell surface markers which distinguish the various cell lineages.
Eventually, these progenitor cells decrease the expression of immature cell-surface
markers (i.e. c-kit+) and differentiate into erythroid (red blood cells or platelet-producing
megakaryocytes), myeloid (neutrophils, monocytes/macrophages, eosinophils, and
basophil cells), or lymphoid (natural killer cells and B or T lymphocytes) cells. The
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Figure 1. Hematopoiesis diagram.

Self-Renewal

Multipotency
Self-renewal

Long-term Hematopoietic
Stem Cell (HSC)

HOX genes
c-kit+
Short-term HSC

Common myeloid progenitor

Common lymphoid progenitor

Small lymphocyte
Myeloblast

LineageSpecific
marks
Differentiation
Basophil Neutrophil Eosinophil

Monocyte

T lymphocyte

B lymphocyte

The process by which undifferentiated hematopoietic stem cells (HSCs) give rise
to all types of fully-differentiated blood cells. (Cells of the erythroid lineage—
red blood cells and platelet-producing megakaryocytes—have been omitted from
this diagram for simplicity.)
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differentiated blood cells are released from the bone marrow to circulate throughout the
body or to travel to distant lymphoid tissues like the spleen, thymus, and lymph nodes
where they function as mature cells or (in the case of lymphocytes) undergo further
maturation.
The hematopoietic stem cell niche
The environment in which the blood cells develop influences hematopoiesis.
Extracellular factors from this environment can stimulate hematopoietic cells to
proliferate, differentiate, or mobilize through various signaling mechanisms. During
embryonic development, hematopoiesis takes place in different locations as the fetus
generates new tissues capable of cultivating the blood cells. Initially, hematopoiesis
takes place in blood islands of the yolk sac surrounding the developing embryo before
moving to the aortic-gonadal-mesonephric region. Once the tissues of the liver have
developed, blood cell development moves to the fetal liver and finally to the bone
marrow where hematopoiesis continues throughout adulthood35. In each of these
locations, the maturing hematopoietic cells require a particular set of conditions that
make up a micoenvironment called the HSC niche.
The primary location for hematopoiesis in newborns and adults is the bone
marrow found within the medullary cavities of long bones and the cancellous tissues of
the skull, pelvis, and vertebrae. The marrow has a distinct architecture consisting of a
fibrous network and stromal cells which support the hematopoietic cells. The HSCs are
found deep within the marrow cavities in the periendosteal region where they are in
contact with osteoblasts which line the bone surfaces. Contacts made between these cells
regulate signaling through N-cadherin and Notch1 and are critical for the retention of
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HSCs in the niche and the maintenance of their pluripotent potential

36-38

. Interspersed

throughout the marrow are supportive stromal cells. These cells secrete soluble factors
like G-CSF, GM-CSF, SCF (also known as kit ligand), IL-6, and CXCL12 which are
known to regulate proliferation, differentiation, and mobilization of hematopoietic cells3942

. Nitric oxide (NO) from stromal cells has also been shown to modulate hematopoiesis

and the mobilization of progenitor cells43-45.
Other factors like oxygen availability affect the cells within the HSC niche, and I
hypothesized that oxygen levels may also affect MLL function during leukemogenesis46,
47

. Sinusoidal capillaries weave throughout the marrow to supply oxygen and nutrients to

the niche and to remove metabolic byproducts. The partial pressure of oxygen from
gross marrow aspirates from superior iliac crests of healthy donors has been measured to
be 55 mm Hg in one report (or about 7% compared to 21% O2 in typical ambient air of
cell-culture incubators)48. Given the three-dimensional architecture and cellular
complexity of the bone marrow, however, it is reasonable to envision microenvironments
within the marrow in which there are variable levels of oxygen. The stroma surrounding
the sinusoidal capillaries form layers in which hematopoietic cells found further away
from the capillary would be exposed to lower levels of oxygen as the oxygen diffuses
away from the vessel and is depleted by other intervening, metabolically active cells. In
fact, the oxygen levels in bone marrow have been mathematically modeled to
demonstrate that a range of oxygen pressures likely exists in the marrow given the
presence of intervening acellular fibers, single cells, or colonies of proliferating cells that
separate hematopoietic cells from the sinusoidal capillaries49, 50. These models suggest
that the less mature, progenitor cells are positioned in the regions with lowest oxygen
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tensions (<1% O2) while the more differentiated cells would be found closer to the
capillaries with higher oxygen levels (6-7% O2).
This association between regional oxygen levels in the bone marrow and the
distribution of hematopoietic cells has since been determined in vivo using mice that have
been administered fluorescent Hoechst 33342 (Ho) dye to measure diffusion within the
marrow cavities51. The authors found HSCs to be enriched in the regions with the lowest
perfusion of Ho dye suggesting that oxygen would be less available to these cells. In
fact, treatment with the hypoxia marker, pimonidazole, showed selective targeting of
progenitor cells which were residing in the regions of least perfusion compared to the
more mature hematopoietic cells within areas of greater perfusion. These observations
suggest that the hematopoietic cells are distributed in an organized manner within the
marrow which corresponds to the oxygen availability within the HSC microenvironment.
Subsequent studies in vivo have also confirmed that the hematopoietic precursor cells lie
in regions with low oxygen tension while cells that are more actively proliferating in the
presence of growth factors are positioned near the capillary sinuses of the marrow37, 52.
The effect of low oxygen tension on hematopoietic cells has been measured in vitro.
Progenitor cells grown in culture under hypoxic conditions (1% O2) have shown
increased proliferation potential and increased colony forming ability53-55. These findings
suggest that a hypoxic bone marrow environment may be an advantageous environment
for undifferentiated hematopoietic cells where they can maintain a self-renewing pool of
stem cells56.
The hypoxic niche, however, has also been shown to benefit leukemic stem cells
which rely on similar niche properties for continuous proliferation and evasion of
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57-61
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. With a conserved cysteine residue within the critical CXXC

DNA-binding domain (described in detail below), I hypothesized that the hypoxic niche
would benefit leukemia cells expressing an MLL fusion protein. Under conditions of
hypoxia, this cysteine—with a sulfhydryl side chain susceptible to post-translational
modification—could be more readily kept in a reduced state which would allow the
fusion protein to bind to its DNA targets and subsequently maintain gene expression and
the undifferentiated cell state. In contrast, exposure to higher levels of oxygen could
potentially lead to oxidation of the thiol side chain that would disrupt MLL’s ability to
bind to DNA causing the cells to decrease proliferation and undergo differentiation.
HOX cluster genes and MLL
During hematopoiesis, a specific set of gene regulatory events occur that allow a
cell to progress from a pluripotent HSC to a fully-differentiated blood cell of a particular
lineage. One set of highly regulated genes called the HOX cluster genes were first
implicated in the process of hematopoiesis when progenitor cells were found to display
unique expression patterns of subsets of HOX genes: the expression of HOX genes was
decreased when cells underwent differentiation toward erythroid or myeloid lineages62.
The name of the HOX genes is derived from a conserved DNA-binding domain (the
homeobox domain) found in homeotic proteins which were first implicated in Drosophila
development63. Groups of multiple HOX genes form gene clusters that have been found
to be evolutionarily conserved in metazoans from the fruit fly to chickens and humans
suggesting that this set of homeobox-containing genes plays a critical role during
development64, 65. Subsequent studies in mice and humans confirmed the developmental
role of HOX genes (Hox in mice) in embryonic patterning where differential expression
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Figure 2 . The HOX genes are an evolutionarily conserved set of genes
involved in development and hematopoiesis.

The HOX cluster genes are conserved throughout evolution from fruit flies
(Drosophila melanogastor) to humans and are organized in a pattern which
corresponds to their role in the determination of segmental identity during
development. (This figure was reproduced from the book Your Inner Fish by Neil
Shubin with permission from the illustrator, Kalliopi Monoyios, University of
Chicago).73
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of various HOX family members in spinal tissue corresponds to the determination of
segmental identity66-68. Differential expression of these homeobox-containing genes from
flies to humans helps to establish polarity in the embryo so that an anterior-posterior
orientation can develop along the central axis69, 70. The spatial orientation of these genes
closely corresponds with their role in determining segmental identity, and this gene
structure has been evolutionarily conserved in eukaryotes from invertebrates to
vertebrates (Figure 2)71-73. In contrast to invertebrates which have homebox genes
arranged linearly in a single cluster, the 39 HOX genes in humans are organized in four
distinct clusters—HOXA, HOXB, HOXC, and HOXD—each containing 9-11 HOX genes.
This clustered arrangement allows each subset of genes to be under the same
transcriptional regulatory control for coordinated, temporospatial expression74, 75.
A critical role for MLL in Hox cluster gene regulation was demonstrated in
heterozygous Mll +/- and null Mll -/- mice12. Mll -/- mice are embryonic lethal by day
E10.5 while the heterozygous mutants survive through birth with defects in axial skeletal
formation associated with the misexpression of Hoxa7 and Hoxc8 compared to wild type
Mll +/+ mice. These defects demonstrate haploinsufficiency (Mll +/- mice with loss of a
single allele exhibited phenotypic defects) and indicate an important role for MLL in the
regulation of Hox genes during development. Furthermore, heterozygous Mll +/- mice
showed decreased levels of erythrocytes, hemoglobin, and platelets suggesting the loss of
Mll also impairs hematopoiesis12. It was subsequently shown that loss of both Mll alleles
prevents the sustained expression of Hox genes leading to the observed developmental
defects and impaired embryonic hematopoiesis in both the yolk sac and fetal liver76-78.
More recent findings using a loss-of-function mutant have confirmed the role of MLL in
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adult hematopoiesis in which postnatal mice are unable to sustain normal blood cell
development beyond three weeks following targeted gene excision79, 80. Taken together,
these findings show that MLL plays an important role in maintaining the proper
temporospatial regulation of Hox cluster genes that is required during both embryonic
development and during fetal and adult hematopoiesis.
The HOXA9 gene is a well-studied HOX cluster gene with regard to its role in
hematopoiesis and MLL leukemia. The initial association between HOXA cluster genes
and hematopoiesis was suggested from observations that undifferentiated progenitor cells
show higher HOXA cluster gene expression levels than more mature hematopoietic
cells81. Subsequent studies demonstrated a role for HOXA9 in the transformation of
myeloid cells through a t(7;11)(p15;p15) translocation which generates a leukemogenic
NUP98-HOXA9 fusion transcript and through the cooperation of MEIS1 with HOXA98284

. Together Hoxa9 and Meis1 function as a heterodimeric transcription factor to bind to

DNA targets through the homeobox domain. The functional significance of this
cooperativity has been verified in vivo through the transplantation of primary bone
marrow cells that overexpress both Hoxa9 and Meis1. These cells lead to overt leukemia
in recipient mice within three months. The role of Meis1 in MLL associated leukemia
was further verified by knocking down Meis1 in MLL-AF9 transformed hematopoietic
cells resulting in delayed leukemia progression in vivo85, 86.
The transformation of primary hematopoietic cells by MLL fusion proteins was
shown to be mediated through upregulation of Hoxa cluster genes which subsequently
cooperate with Meis187. Specifically, a MLL oncoprotein is required for maintaining the
expression of Hoxa7 and Hoxa9 in primary bone marrow cells to sustain immortalization
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in vitro. This critical role of MLL in HOX gene regulation was further demonstrated
during embryoid body differentiation in which embryonic stem cells are stimulated in
vitro to undergo coordinated differentiation to form hematopoietic progenitor cells
followed by mature hematopoietic cells. Mll null progenitor cells show marked reduction
in Hoxa, Hoxb, and Hoxc cluster genes compared to Mll heterozygous cells during
embryoid body differentiation88. These Mll deficient embryoid body cells are capable of
proliferating like the heterozygous counterparts but show reduced colony forming ability
in vitro suggesting that positive regulation of Hox genes by Mll is necessary during the
early stages of hematopoiesis in order to maintain the progenitor population from which
the mature blood cells arise.
The role of MLL in transcriptional regulation
Regulation of HOX gene expression is multifaceted involving large transcriptional
complexes which can bind to multiple promoters within each cluster of genes, alternative
splicing of the various gene transcripts, and regulation by microRNAs and long noncoding transcripts75, 89, 90. The detailed mechanism by which MLL directly regulates the
expression of HOX cluster genes is actively being studied and has been shown to involve
multiple domains of the large MLL protein (431 kDa) (Figure 3A).
The MLL protein is a homolog of Drosophila trithorax and is a member of the
SET (Suppressor of variegation, Enhancer of zeste, Trithorax) family of histone
methyltransferases1, 91. With the intrinsic enzymatic activity of its SET domain, MLL
catalyzes trimethylation of lysine 4 on histone 3 (H3K4me3), a modification which is
associated with active gene transcription92. Interestingly, homozygous deletion of the
exons encoding the SET domain from both Mll alleles leads to decreased H3K4
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Figure 3. Structural schematic of MLL, a MLL fusion, and MLL2
proteins.
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(A) The MLL protein is comprised of multiple functional domains. Leukemiacausing fusion proteins necessarily retain the N-terminal domains of MLL including
the menin-binding domain, AT hooks, and CXXC DNA-binding domain. The
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boxes, respectively. The conserved Taspase I cleavage sites are indicated by
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(B) MLL2 shares the same organization and types of functional domains as MLL.
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methylation in Hox promoters and decreased expression of several Hox genes; this
deletion, however, does not recapitulate the embryonic lethality of the Mll null mice93.
This finding suggests that the histone methyltransferase (HMT) activity of MLL’s SET
domain helps to promote Hox gene activation but that the HMT activity is not the only
function of MLL that contributes to gene regulation during development. The ability of
MLL to regulate HOX gene transcription during normal hematopoiesis or during
misregulated leukemogenesis is also dependent on other functional domains of MLL and
on MLL’s ability to localize to the nucleus2, 80, 94, 95.
MLL is proteolytically cleaved by Taspase I separating MLL into N- and Cterminal fragments which associate through internal FYRC and FYRN domains and
localize to the nucleus96, 97. The N-terminal fragment of MLL can bind directly to DNA
through several domains: a set of three AT hooks and a zinc-binding domain called the
CXXC domain (discussed in detail below)3, 98. These AT hook motifs recognize AT rich
or bent regions of DNA, and the CXXC domain recognizes non-methylated CpG
dinucleotides2, 3, 5, 11. These DNA sequences recognized by MLL are relatively
ubiquitous, so targeting of MLL to specific genes must occur through associations with
other proteins that can provide greater specificity. Interaction with menin (and the
subsequent recruitment of lens epithelium-derived growth factor, LEDGF, a
transcriptional co-regulator) and associations with E2F and host cell factor (HCF)-1 have
been shown to help target MLL to specific regions of DNA and facilitate
transformation99-104. Through its interaction with menin, MLL functions in a larger
complex consisting of Ash2L, WDR5, Rbbp5, Dpy30, and HCF to regulate gene
transcription105. The critical menin-binding and DNA-binding domains are found within
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the N-terminal portion of MLL and are required for the leukemogenic activity of MLL
fusion proteins which induce immortalization and subsequently cause leukemia (Figure
3A)2, 4, 94.
MLL also contains a group of PHD finger domains which are commonly found in
chromatin-associating proteins. The third PHD finger of MLL binds to both H3K4me3
histones and to the peptidyl-prolyl cis-trans isomerase Cyclophilin 33 (Cyp33) through
the RNA-recognition motif (RRM) domain106-108. Together these interactions help MLL
regulate target Hox gene expression through the prolyl isomerization activity of Cyp33
which decreases MLL’s ability to bind to the H3K4me3 mark on histone tails106, 109. In
MLL fusions, this third PHD finger is necessarily absent so that Cyp33 cannot be
recruited to repress the transcriptional activation of target genes facilitated by the fusion
protein110.
The CXXC domain of MLL is located within a larger region of MLL termed the
repression domain (amino acids 1100-1400) (Figure 3A). The repression domain was
functionally named for its ability to suppress reporter gene expression in contrast to the
activation domain in the C-terminus of MLL (residues 2340-3123) which showed
increased expression in the same assay3. Our lab has previously shown that the
repression domain directly interacts with co-repressor proteins—histone deacetylases 1
and 2 (HDACs 1 & 2), polycomb group proteins (HPC2 & BMI-1), and C-terminalbinding protein (CtBP)—although the individual residues of MLL with which they
interact have not yet been determined8. HDACs 1 & 2 have enzymatic activity for
removing acetyl groups from lysine residues on histone tails. This restores a positive
charge to the side chain of histone lysines and increases histone affinity for the negatively
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charged phosphate backbone of the DNA to effectively maintain a closed,
heterochromatin state.
The activating functions of MLL (a member of the Trithorax group of proteins)
are opposed by the repressive functions of Polycomb group proteins111. The interplay
between Trithorax and Polycomb group (PcG) proteins provides tight regulation of gene
expression that is necessary for proper segmental development in the embryo112. In the
adult, the balance between these two groups of activator and repressor complexes helps to
maintain proper gene expression during hematopoiesis. BMI-I and HPC2 are both
members of the polycomb repressive complex 1 (PRC1) which recognizes the repressive
H3K27me3 mark placed by the PRC2 complex113. HPC2/CBX4 is the human polycomb
group 2 protein that was first identified by Satijn et al. as a repressor protein with a
highly conserved C-terminal binding domain114. HPC2 functions as a core component of
the Polycomb Repressive Complex 1 (PRC1) along with BMI-1, RING1, and
polyhomeotic homolog (Ph) proteins. With its distinct chromodomain, HPC2 recognizes
and binds H3K27me3 marks that are catalyzed by EZH2 of the PRC2 complex and
recruits RING1 (and subsequently, the rest of the PRC1 complex) through the C-terminal
domain to repress transcription111, 114-116. The polycomb group proteins function to
establish and maintain a heterochromatic state that represses gene transcription. CtBP
can cooperate with PcG proteins to repress transcriptional activity through its direct
interaction with HPC2117. CtBP has been implicated in tumorigenesis through the
repression of tumor suppressor genes118, 119.
In MLL-associated leukemia, however, the balanced transcriptional regulation of
MLL target genes is disrupted by the fusion of a partner protein to MLL. The N-terminus
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of MLL is often fused to the C-terminal sequence of a protein, commonly a partner
protein that is found in transcription elongation complexes28. The recruitment of a fused
transcriptional coactivator to MLL target genes is thought to cause uninhibited gene
expression through the subsequent recruitment of factors which mediate transcriptional
elongation120-122. This gene activation through the fused partner protein overcomes the
transient associations of the repressive PcG complexes leading to gene misregulation and
ultimately leukemia123, 124.
The CXXC domain and ‘post CXXC’ residues of MLL were recently shown to
interact with the coactivator Polymerase Associated Factor (PAF) protein9, 10. PAF is a
component of the PAF complex (PAFc) comprised of PAF1, RTF1, Ctr9, Leo1, and
Cdc73 protein subunits which were identified through association with the COMPASS
complex containing members of the Trithorax family125. PAFc cooperates with
elongating RNA polymerase II to enhance transcription and was shown to be necessary
for introducing activating epigenetic marks (i.e. methylation of H3K4 and H3K79) during
active gene transcription125-127. In MLL fusions, the PAF1 subunit directly interacts with
the residues flanking the CXXC domain and mutation within the CXXC domain can
disrupt this interaction9, 10. PAFc was shown in these studies to enhance Hox gene
expression mediated by a MLL-AF9 fusion, and disruption of the PAF1 interaction
resulted in decreased recruitment of the MLL fusion to Hox gene promoters, a subsequent
decrease in Hox expression, and loss of transformation capacity in vitro.
MLL functions in the context of a large network of proteins that are associated
with transcriptional activation and elongation, and association with Polycomb Group
proteins helps to moderate the transcriptional activation of MLL target genes. Within
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these larger transcriptional complexes, wild type MLL functions to maintain active gene
transcription through the HMT activity of the SET domain and by protecting
unmethylated promoter regions of target genes via the CXXC domain further facilitating
gene expression92, 128, 129. In contrast, MLL fusions alter this carefully regulated
transcription to cause overexpression of homeotic genes that maintain hematopoietic cells
in an undifferentiated state. It has recently been shown that the MLL-AF9 fusion protein
requires a normal allele of MLL to maintain transcription of gene targets130. Together the
wild type MLL protein and the MLL fusion protein alter hematopoiesis by localizing to
and driving increased expression of a subset of genes that are normally regulated by wild
type MLL131, 132.
MLL2 is the closest homolog of MLL
MLL (also known as MLL1) is the founding member of the MLL family of SET
domain-containing H3K4 histone methyltransferases of which there are five members
(numbered 1 to 5). The closest homolog of MLL is MLL2, whose gene is located at
chromosomal band 19q13.16. (Note that MLL2 is officially named MLL4 by the Human
Genome Organization Gene Nomenclature Committee, though, in the literature these
names have been shared with a less homologous member of the MLL family known as
ALR-1; MLL2—as I will refer to the closest homolog of MLL that was studied in this
dissertation—has also less commonly been referred to as TRX2, HRX2, KMT2b, WBP7,
and KIAA0304.) While the MLL2 transcript is shorter than MLL (8.5 versus 12.5 kb),
both genes are encoded by 37 exons and retain the same number and orientation of
functional domains including the AT hooks, CXXC DNA-binding domain, PHD fingers,
and SET domain (Figure 3B)6, 133. The large MLL2 protein (290 kDa) is proteolytically
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cleaved by Taspase I in the same manner as MLL

134

. Together, these findings suggest

that a gene duplication occurred in vertebrates and that the duplicated genes have
subsequently evolved into the two closely related proteins MLL and MLL26.
Like MLL, MLL2 is ubiquitously expressed throughout the body6, 135. However,
MLL2 is not a functionally redundant paralog of MLL. MLL and MLL2 knockout mice
are both independently embryonic lethal with death by day E10.5 versus E11.5,
respectively, suggesting that loss of one of these MLL family members cannot be
compensated by the other136. Embryos of Mll2 null mice show growth retardation,
delayed differentiation, and increased cellular apoptosis136, 137. Decreases in Hoxb1 and
Mox1 expression were observed in somites surrounding the neural tube of Mll2 null
embryos, reminiscent of the axial changes observed in development of Mll deficient
embryos12, 136.
MLL2 associates with a similar transcriptional activation complex as MLL to
regulate Hox gene transcription. Like MLL, this complex includes menin, Ash2L,
Rbbp5, WDR5, CpG binding protein (CGBP/CFP1), and Dpy30105, 138, 139. Of
importance, MLL and MLL2 do not co-exist simultaneously within the same purified
transcriptional complexes, further confirming distinct roles for these two paralogs140. In a
study of global H3K4me3 patterns in mouse embryonic fibroblasts (MEFs), Mll -/- cells
showed decreased H3K4me3 within the Hoxa and Hoxb cluster and no change in
trimethylation within the Hoxd cluster129. When menin was knocked out in MEFs, a
decrease in trimethylation within the Hoxa and Hoxb loci was observed with a significant
reduction of H3K4me3 within the Hoxd locus. Since MLL and MLL2 both interact with
menin during transcriptional regulation, it seems that H3K4 trimethylation within the
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Hoxd locus does not depend on MLL (H3K4me3 persisted in Mll -/- mice) but instead is
dependent on another histone methyltransferase—likely MLL2—which also requires
menin for H3K4 trimethylation. Other studies looking at the effects of the loss of Mll2 at
specific loci have shown decreased expression of Hoxb1, -2, and -5 and Mox1 (with
unaffected Hoxa1 expression) and decreased H3K4me3 in the promoter regions of Bcl2
and Magoh2136, 137, 141. Broader screening for MLL2 target genes has yet to be conducted
to better understand how the role of MLL2 is distinct from that of MLL. It is also not
known whether MLL2 interacts with the same co-repressor proteins that were previously
identified by our lab to interact with the MLL repression domain (HDAC1/2, HPC2,
BMI-1, and CtBP)8. The first aim of my dissertation was to determine if these
interactions are also conserved between these two homologs.
Given the structural and functional similarities between MLL and MLL2, it is
intriguing that only two reports to date have suggested involvement of MLL2 in
tumorigenesis133, 142. Several solid tumor types have shown gene amplification of MLL2
(pancreatic or glioblastoma cell lines) or overexpression of MLL2 protein (invasive
breast and colon cancer cell lines) compared to normal tissue. Interestingly, MLL2
translocations have not yet been found in leukemia. When expressed by retrovirus, an
experimentally derived MLL2-ENL fusion containing the same critical N-terminal
domains found in MLL fusions (Menin-binding domain, AT hooks, and CXXC domain)
was unable to transform primary hematopoietic cells in vitro7. Transformation capacity
of these cells could be rescued by the chimeric fusion protein only when sequences that
included the MLL CXXC domain were introduced in place of the MLL2 sequence (MLL
residues 1050/1149 to 1337). This finding suggests that there are specific differences in
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amino acids within the CXXC domains of MLL and MLL2 that alter the ability of the
fusion proteins to transform hematopoietic cells. The first aim of my dissertation focuses
on these specific amino acid differences between the CXXC domains of MLL and MLL2
to determine which, if any, of the residue differences contribute to the leukemogenic
capacity of MLL fusion proteins.
The MLL CXXC Domain
The CXXC DNA-binding domain of MLL was first identified as a region having
homology to a domain found in DNA methyltransferases98. This domain is found in the
N-terminus of both MLL and MLL2 and shown to bind to unmethylated CpG
dinucleotides2, 5, 11. This domain is necessarily retained in MLL fusion proteins that have
the capacity to generate leukemia and helps to maintain active expression of target Hox
genes by preventing repressive promoter methylation2, 5, 11, 128. The CXXC domain is
named for the spacing of eight cysteine residues within this domain which coordinate two
zinc molecules (Figures 4 and 5). The spacing of these cysteines is conserved across
MLL homologs of vertebrate and invertebrate species and also found in MLL2 and other
mammalian proteins. Four cysteines each coordinate one zinc ion through their reduced,
sulfhydryl sidechains to generate a stable, tetrahedral Zn-binding motif. This motif varies
from a classical Zn-finger structure in that the coordinating cysteine residues are not
sequentially organized (Figures 4A and 5B)11, 143.
The CXXC domain is a crescent-shaped structure in which the interior surface
forms direct interactions with its target DNA (Figure 5). This domain preferentially
binds to non-methylated CpG DNA sequences through electrostatic interactions and
hydrogen bonding5, 11. The CXXC domain is essential for in vitro transformation of cells
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Figure 4. The MLL CXXC domain is conserved across species, and
similar domains are found within other proteins.
A

B

(A) Sequence alignments of MLL CXXC domains from various eukaryotes and
other CXXC-domain containing proteins showing highly-conserved spacing of
zinc-coordinating cysteines (yellow) and the non-zinc-coordinating cysteines
aligning with Cys1188 of hMLL (red). The coordination of the first (1) and
second (2) zinc ions by the conserved cysteine residues is indicated below.
(Alignments courtesy of Manuel Diaz, MD, Loyola University Chicago.)
(B) Phylogenetic tree showing the homology between various mammalian
CXXC domains (reproduced from Figure 1C of Frauer et al.144).
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Figure 5. Comparison of the MLL and MLL2 CXXC domains.
A
MLL aa1147 KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSK aa1203
MLL2 aa958 GKKMRMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARKME aa1014
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(A) Sequence alignment of the MLL (aa1147-1203) and MLL2 (aa958-1014)
CXXC domains highlighting zinc-coordinating cysteines in yellow, Cys1188 of
MLL in red, and non-conserved residues of interest in blue. (B) Solved solution
structure of the MLL CXXC domain (green ribbon) in complex with DNA (ball
and stick) from PDB ID 2KKF. (C) Threaded model of the MLL2 CXXC domain
based on the solved MLL structure. (D) Amino acids that were selected to study in
Aim 1 by introducing the MLL residue into the MLL2 CXXC domain.
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expressing the MLL-ENL fusion protein . Mutation in any of the eight, Zn-coordinating
2

residues inhibits oncogenic capacity of these cells due to destabilization of the protein
structure and loss of DNA binding2, 143. Based on the NMR structure of this domain
solved both in the presence and absence of CpG-containing DNA, Laurie Risner, PhD, in
our lab has recently introduced point mutations into the MLL CXXC domain which do
not disrupt folding of the domain11. When mutations of the MLL-AF9 CXXC domain
were introduced into residues that directly interacted with DNA (R1154A, K1185A,
Q1187A), a decrease in DNA-binding affinity was observed compared to the wild type
MLL CXXC domain in conjunction with a loss of in vitro transformation capacity of
these mutant MLL-AF9 fusions in colony forming assays. This evidence demonstrates
that MLL fusion proteins require the DNA binding capacity of the CXXC domain for the
development of acute leukemia.
There is one cysteine residue—Cysteine 1188—in the MLL CXXC domain which
does not coordinate with the zinc molecules (highlighted in red in Figures 4-6). It is
located adjacent to a conserved, Zn-coordinating cysteine (Cys1189) and is critically
positioned on the surface of the DNA-binding interface11. The thiol group of a cysteine
side chain is particularly susceptible to biochemical changes via redox reactions and posttranslational modification13. Much research has been reported on the regulation of
transcription factor binding to DNA13, 145-150. In many instances, this regulation occurs at
sites of cysteine residues within a Zn-coordinating structure. Zinc-binding motifs
containing a zinc ion tetrahedrally coordinated to cysteine or histidine groups are
relatively common within DNA-binding proteins including SP1, NF-κB, p53, TFIIH,
estrogen receptor, and estrogen related receptor-2 (ERR-2)13. The functions of such
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transcription factors have been subject to modulation by redox reactions as determined by
site-directed mutagenesis studies and treatments with oxidizing or reducing agents
leading to altered DNA-binding affinity or altered target gene expression13, 147, 151. The
DNA-binding domains of p53, TFIIH p44, and ERR-2 all contain an additional cysteine
residue which does not coordinate zinc and physiologically modulate protein binding to
DNA to function as a molecular switch152-154.
The non-Zn-coordinating cysteine of the MLL CXXC domain, Cys1188, is
conserved in the MLL orthologs of vertebrates but is noticeably absent in more distant,
invertebrate species (Figure 4A). Interestingly, epigenetic regulatory mechanisms (i.e.
those involved with methylation of gene promoters) have simultaneously diverged during
eukaryotic evolution155-158. These parallel evolutionary phenomena support the
hypothesis that Cys1188 in the CXXC domain of MLL may be functioning as a
molecular switch to regulate the binding of CXXC to its HOX gene targets.
Cysteine 1188 does not directly interact with DNA through hydrogen bonds or
salt bridges but is located on the DNA-binding surface of the MLL CXXC domain11.
When this residue was mutated to alanine (C1188A), the transduced MLL-AF9 construct
was able to immortalize hematopoietic progenitor cells with efficiency similar to wild
type MLL-AF9 in a colony formation assay11. The DNA-binding affinity was also found
to be equal to that of the wild type CXXC domain. In contrast, when this Cys1188
residue was mutated to aspartate (C1188D), a repulsive negative charge was introduced
into the domain which disrupted DNA binding resulting in a loss of colony forming
ability, even though the domain retained appropriate folding. In vivo transplantation of
bone marrow cells expressing MLL(C1188A)-AF9 or MLL(C1188D)-AF9 into mice
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confirmed the in vitro results showing that functional binding of the MLL CXXC domain
to DNA is required for the development of leukemia. Of note, mutation of Cys1188 to
inert alanine (which is not susceptible to regulation by post-translational modifications)
led to a shorter latency of leukemia development compared to the wild type Cys1188
(median survival of about 40 versus 90 days)11. With a critical position on the DNAbinding surface and a sulfhydryl side group susceptible to post-translation modification,
this Cys1188 residue may serve a functional role within the MLL CXXC domain to
regulate MLL’s binding to HOX gene targets.
This non-zinc-coordinating cysteine residue is conserved in the MLL2 CXXC
domain. There are, however, a number of other amino acids which differ between MLL
and MLL2 within the CXXC domain (Figure 5). The goal of the first aim of my
dissertation was to study the functional differences between the residues of the MLL2
CXXC domain and those of the MLL CXXC domain to understand how specific residues
of MLL contribute to leukemia. Based on the alignments of the MLL and MLL2 CXXC
domains (Figure 5A), the solved CXXC domain structure of MLL (Figure 5B), and the
threaded model of the MLL2 CXXC domain (Figure 5C), strategic amino acid
substitutions were introduced into the MLL2 CXXC domain (Figure 5D). Eleven of the
thirteen substitutions that were studied are positioned between the conserved cysteine
residues which coordinate the zinc ions. Since the structural cysteine residues allow the
MLL CXXC domain to form a stable domain, I predicted that these non-conserved
residues of the MLL2 CXXC domain would be found in a similar position within the
MLL2 CXXC domain yet alter the overall DNA- or protein-binding function(s) of the
domain. Two additional amino acid substitutions of the CXXC domains that were also
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Figure 6. Comparison of amino acid differences within the MLL
and MLL2 CXXC domains to be studied in Aim 1.
MLL aa1147 KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSK aa1203
MLL2 aa958 GKKMRMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARKME aa1014
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Four surfaces of the MLL CXXC domain colored according to the sequence
alignment above in which blue residues represent amino acid substitutions that
were introduced into the MLL2 CXXC domain to restore the residue(s) to the MLL
sequence.
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studied (A964R and R1011M) are positioned outside of the boundaries defined by the
conserved, structural cysteines. These residues are found in close proximity to one
another within the MLL CXXC domain and near the DNA. They were predicted to alter
DNA-binding affinity, so these substitutions were also introduced into the MLL2 CXXC
domain for studying their contribution to MLL function. The specific amino acid
differences that were studied in my dissertation are highlighted in blue on the structural
model of the MLL CXXC domain in Figure 6. I predicted that amino acid differences
between the MLL and MLL2 CXXC domains would contribute to variable DNA-binding
affinities or to variable interactions with other cofactor proteins depending on the location
of the specific residues within the CXXC domain. Amino acid substitutions on the
interior surface of the domain may alter DNA-binding affinity. In contrast, substitutions
on the outer surface of the domain may alter binding of cofactor proteins to affect overall
function of the fusion protein or may indirectly contribute to altered CXXC DNA-binding
affinity through allosteric effects. The goal of my first project aim was to explore how
specific amino acid differences between the MLL and MLL2 CXXC domains affect the
critical functioning of the CXXC domain and alter the transformation capacity of
leukemogenic fusion proteins.

CHAPTER 3
METHODS
Cloning of MLL/MLL2-AF9 fusion constructs for in vitro colony assay
The wild type MLL2 CXXC domain was PCR amplified from a pcDNA4-HisMaxB plasmid containing the entire exons 1-37 of MLL2 (NCBI Accession Number
NM_014727, courtesy of Kevin FitzGerald, S.J., PhD, Georgetown University) using a
high-fidelity, cloned Pfu DNA polymerase (Stratagene, #600159) and using primers with
AatII and BamHI restriction sites on the ends of the forward and reverse primers (Table
2, A). (Priming sites of cloning primers are depicted in Table 2, and the primer
sequences are listed in Table 3.) The blunt end PCR product consisting of the MLL2
CXXC domain (nucleotides 2872-3042) with the flanking restriction sites was ligated
into a pCR-Blunt holding vector in a 10µL reaction volume for 1 hour at 16°C using T4
DNA Ligase (Fermentas, #EL0014). 1µL of the ligation reaction mixture was
transformed into 50µL of chemically competent OneShot® Top10 Competent E.coli cells
according to the Zero Blunt® PCR Cloning Kit protocol (Invitrogen, #K2750; #C4040).
The accuracy of the MLL2 CXXC insert was verified by DNA sequencing (ACGT, Inc.,
Wheeling, IL) using the M13R primer (Table 2, B; sequencing primers and priming sites
are indicated in gray). The pCR-Blunt-MLL2-CXXC construct was purified using the
GeneJETTM Plasmid Miniprep Kit (Fermentas, #K0503) as were all subsequent plasmids
used in the cloning of the fusion constructs. All plasmid concentrations following
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Mutation
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MLL 1119F
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AF9 Rev

MLL 1119F
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Cloning
Sequencing
Primer(s)
Primer(s)

Table 2. Cloned DNA constructs showing restriction enzyme cutting sites and priming sites which were
used for subcloning and sequencing.

FLAG
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Table 3. MLL and MLL2 cloning and sequencing primers
Amplicon
MLL2 CXXC
MLL2 ‘post-CXXC’
MLL RD
MLL 1/2 RD
Amplicon
M13R (universal)
MLL 1119F
AF9 Rev
T7 Term (universal)

Cloning Primers
Primers (5’ to 3’)
For: GGG ACG TCG AGG CAA GAA GAT GCG CAT GGC TCG ATG
Rev: GGG GAT CCT TCC ATC TTC CGA GCC TCT ATT TTG TC
For: GGG GAT CCC GAC TGG CTA AAA AAG GCC GG
Rev: GGG TCG ACA CGG ACG CGG TGC ACA CC
For: GGT CGC GAG AAC GAG AAA AGA TTT TGT CTT CC
Rev: GGG TCG ACT CTG ATC CTG TGG ACT CC
For: GGT CGC GAG AAC GAG AAA AGA TTT TGT CTT CC
Rev: GGG TCG ACA CGG ACG CGG TGC ACA CC
Sequencing Primers
Primers (5’ to 3’)
GGA AAC AGC TAT GAC CAT G
CAG AAG ATG CTG AAC CTC TTG CTC C
GGG TCG ACA CGG ACG CGG TGC ACA CC
GCT AGT TAT TGC TCA GCG G

miniprep isolation were determined using 2µL of eluted plasmid DNA with a NanoDrop
2000 (Thermo Scientific) prior to submitting sample(s) for sequencing or prior to
subsequent digestion.
A novel construct encoding the N-terminal fragment of MLL (nucleotides 1-4212)
was previously generated by Laurie Risner, PhD. This construct contains 5’-AatII and
3’-BamHI restriction sites flanking the nucleotide sequence encoding the MLL CXXC
domain for conveniently swapping in mutant or alternative sequences (while still
maintaining the original reading frame of MLL: NCBI Accession Number L04284)11
(Table 2, D). This 5’-fragment of MLL (pMCS5 vector) and the sequence encoding the
MLL2 CXXC domain (pCR-Blunt vector) were subjected to double digestion with AatII
(New England Biolabs, NEB) and BamHI (NEB) restriction enzymes in 40µL reaction
volumes at 37°C for 1-2 hours in NEB Buffer #4 to release the respective sequence
encoding the CXXC domains from the vectors. Both reactions were heat inactivated at
65°C for 15 minutes. Calf intestinal alkaline phosphatase, CIP (NEB, #MO290S), was
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added to the digested pMCS5 vector containing the digested 5’-MLL fragment (35
minute incubation at 37°C) to prevent self-ligation of the vector by removing the terminal
5’-phosphate. The digestion products were then separated by electrophoresis on a 1%
agarose gel or a 4% NuSieve® 3:1Agarose (BiWhittaker Molecular Analysis—BMA,
#50090) gel at 90V for 30min. The respective bands were gel purified with the Qiaex®
II Gel Extraction Kit (Qiagen, #20051) and ligated together for 2 hours at 14°C to create
a 5’ construct encoding the chimeric MLL/MLL2(CXXC) domain (Table 2, E). 5µL of
the ligation reaction mixture was used to transform 50µL of chemically competent DH5α
E.coli cells according to supplier’s protocol (NEB, #C2988J). This construct was
sequenced with the MLL 1119F primer which anneals at MLL nucleotide 3355 just
upstream of sequence encoding the CXXC domain to ensure that the swap of the MLL
and MLL2 sequences was successful and to ensure that the correct reading frame was
maintained through the restriction sites.
The ‘post-CXXC’ region of MLL2 (nucleotides 3043-3522) was cloned from the
full length MLL2 construct using high fidelity PCR amplification as described above, this
time, with forward and reverse primers containing BamHI and SalI restriction sites,
respectively (Table 2, A). The blunt PCR product was ligated into a pCR-Blunt vector
and transformed into Top10® chemically competent E.coli as described above. The
insert was sequenced to verify its accuracy using the M13R primer (Table 2, C).
To exchange the ‘post-CXXC’ region of MLL and MLL2, the chimeric pMCS55’ MLL/MLL2(CXXC) construct and the pCR-Blunt-MLL2 ‘post-CXXC’ constructs
were doubly digested with BamHI (NEB) and SalI (NEB) in the same reaction conditions
as above and the products were separated on a 1% agarose or 4% NuSieve® 3:1Agarose

38
gel by electrophoresis (90V for 30min). The appropriate fragments were then gel
purified and ligated at 14°C for 4 hours to form the pMCS5-5’ MLL/MLL2(CXXC +
‘post-CXXC’) construct (Table 2, F). 2µL of the ligation mixture was used to transform
50µL of DH5α E.coli cells (NEB). The plasmid DNA was purified, and the insert
accuracy was verified by sequencing with the MLL 1119F primer.
The wild type fusion construct, pMSCVneo-MLL-AF9, was previously cloned in
our lab by Laurie Risner, PhD. This construct was used for subsequent studies as the
highly-transforming, positive control and also served as the source of the 300-bp AF9
fusion partner for the MLL/MLL2 constructs (Table 2, G). The 3’-end of AF9 (NCBI
Accession Number AK301474)—which is fused to a sequence encoding a FLAG tag at
the 3’ end—was digested from the pMSCV-MLL-AF9 with SalI (Promega) and BglII
(NEB) in a 30µL reaction volume with Buffer H (Pharmacia) overnight at 37°C. This
digestion reaction was heat inactivated as done previously, the products separated by
electrophoresis on a 2% agarose gel (90V for 45 minutes), and gel purified for use in a
three-way ligation reaction.
The empty vector, pMSCVneo (used for retroviral expression in mammalian
packaging cells), was linearized by double digestion with EcoRI (Gibco) and BglII
(NEB) in a 20µL reaction volume with Buffer H (Pharmacia) overnight at 37°C. This
digestion reaction was heat inactivated and treated with CIP as before to prevent selfligation of the vector. The linearized plasmid was purified through electrophoresis and
gel extraction. The 5-’MLL/MLL2(CXXC ± ‘post-CXXC’) nucleotide sequence was
released from the pMCS5 vector by digestion with EcoRI (Gibco) and SalI (Invitrogen)
in a 50µL reaction volume with Buffer H (Pharmacia) for 2-3 hours at 37°C. The
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digestion products were purified by gel extraction following electrophoresis on a 0.8%
agarose gel for 45 minutes for optimal separation between the 4.2 kb insert and the ~3kb
plasmid (Table 2, E & F).
To complete the cloning of the final fusion constructs, a three-way ligation
reaction was conducted in which the EcoRI/BglII-linearzied pMSCVneo plasmid (6.5kb),
the SalI/BglII-digested fragment of AF9 (300bp), and one of the EcoRI/SalI-digested 5’MLL/MLL2(CXXC ± ‘post-CXXC’) fragments were combined in a 1:5:2 molar ratio
with T4 DNA ligase (Fermentas) in a 10µL reaction volume overnight (nearly 24 hours)
at 14°C. 1µL of three-way ligation mixture was added to 20µL of freshly thawed
ElectroMAXTM DH5α-ETM E.coli cells (Invitrogen, #11319-019) while on ice. This cell
and ligation mixture was then transferred to a pre-chilled, disposable
microelectroporation chamber (Whatman Biometra, #11608-031) within the Chamber
Safe component for the Cell-Porator electroporation apparatus (Gibco BRL Life
Technologies, #11604). With the Voltage Booster set at 4kΩ and the Pulse Control /
Power Supply set at 330kF capacitance, “Low Ω,” “Fast” charge rate, and switched to
“Charge,” the voltage on the unit was increased above 310V. The “Charge” switch was
flipped to “Arm” allowing the voltage to decrease until exactly 310V was reached at
which point the cells were stimulated with an electrical pulse by pressing the trigger
button. The electrically transformed cells were then transferred to 1mL of pre-warmed
S.O.C. media, incubated for 1 hour at 37°C while shaking at 225rpm, and plated on LB
agar with ampicillin (100µg/mL) selection overnight to allow transformed colonies to
grow. The few colonies that formed were picked from the plate and screened for the
correct insert first by PCR amplification using Taq DNA Polymerase (GenScript,
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#E00007) and secondly via bi-directional sequencing using the proximal MLL 1119F and
distal AF9 Rev primers to ensure sequence coverage across all restriction site junctures of
the large, 4.5kb fusion constructs (Table 2, H and I).
All PCR reactions were performed using a PCR Express Thermal Cycler (Thermo
Hybaid, #HBPX 110). Agarose gel electrophoresis of constructs was conducted using the
Sub-Cell® GT Agarose Gel Electrophoresis System (BioRad) and a low-voltage power
supply (Thermo EC, #EC250-90). All small-scale centrifugations were conducted in a
benchtop Spectrafuge 16M (Labnet, #C0160), and ligation reactions were chilled in a
benchtop MicroCooler IITM (Boekel, #260010).
Generation of and cloning of mutant MLL2 CXXC domain constructs
Site-directed mutagenesis was performed on the isolated MLL2 CXXC domain
within the pCR-Blunt plasmid (Table 2, B) using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene, #200518) in order to introduce residues of the MLL CXXC
domain into the MLL2 CXXC domain. Mutagenesis primers are listed in Table 4.
Performing the mutagenesis reaction on the isolated domain was advantageous as the
small insert size facilitated convenient sequence verification and ensured that unexpected
mutations did not occur during the PCR amplification steps of the mutagenesis reaction.
A high fidelity PfuTurbo DNA polymerase provided with the kit was used to ensure
accuracy of the nucleotide substitution(s).
The kit protocol was followed with some exceptions: 500ng of template pCRBlunt-MLL2 CXXC dsDNA was used for the PCR reactions (instead of the
recommended 5-50ng); the elongation step was run for 4 minutes to allow extension of
the full 3.7kb construct; and the PCR reaction was run for 14 cycles. In the case of two
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Table 4. Site-directed mutagenesis primers used to introduce individual MLL
residues into the MLL2 CXXC domain.
Amino Acid
Substitution
(MLL2  MLL)

Codon Conversion

A964R

GCT  CGT

H968Q

CAC  CAG

R970P

CGG  CCG

V975P

GTG  CCG

LRVQ9736QVPE

CTA+CGT+GTG+CAG
CAA+GTT+CCG+GAG

V982T

GTC  ACC

P993R

CCT  CGT

T995I

ACC  ATC

V1001K

GTA  AAA

VY1001-2KM

GTA+TAC  AAA+ATG

R1011M

CGG  ATG

Primers (5’ to 3’)
For: GCA AGA AGA TGC GCA TGC GTC
GAT GTG GAC ACT GTC
Rev: GAC AGT GTC CAC ATC GAC GCA
TGC GCA TCT TCT TGC
For: ATG GCT CGA TGT GGA CAG TGT
CGG GGC
Rev: GCC CCG ACA CTG TCC ACA TCG
AGC CAT
For: GTG GAC ACT GTC CGG GCT GCC
TAC G
Rev: CGT AGG CAG CCC GGA CAG TGT
CCA C
For: CGG GGC TGC CTA CGT CCG CAG
GAC TGT G
Rev: CAC AGT CCT GCG GAC GTA GGC
AGC CCC G
For: GGA CAC TGT CGG GGC TGC CAA
GTT CCG GAG GAC TGT GGG TCC
TGT GT
Rev: ACA CAG GAC CCA CAG TCC TCC
GGA ACT TGG CAG CCC CGA CAG
TGT CC
For: AGG ACT GTG GGT CCT GTA CCA
ACT GCC TAG ACA AGC
Rev: GCT TGT CTA GGC AGT TGG TAC
AGG ACC CAC AGT CCT
For: CCA AGT TTG GGG GCC GTA ACA
CCA AGA AGC A
Rev: TGC TTC TTG GTG TTA CGG CCC
CCA AAC TTG G
For: TTG GGG GCC CTA ACA TCA AGA
AGC AGT GCT G
Rev: CAG CAC TGC TTC TTG ATG TTA
GGG CCC CCA A
For: CAC CAA GAA GCA GTG CTG TAA
ATA CCG GAA GTG TGA CAA A
Rev: TTT GTC ACA CTT CCG GTA TTT
ACA GCA CTG CTT CTT GGT G
For: GCC CTA ACA CCA AGA AGC AGT
GCT GTA AAA TGC GGA AGT GTG
ACA AAA TAG AGG
Rev: CCT CTA TTT TGT CAC ACT TCC
GCA TTT TAC AGC ACT GCT TCT
TGG TGT TAG GGC
For: GTG TGA CAA AAT AGA GGC TAT
GAA GAT GGA AGG ATC CCC C
Rev: CAC ACT GTT TTA TCT CCG ATA
CTT CTA CCT TCC TAG GGG G
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mutagenesis reactions (T995I and R1011M), the PCR reaction was set up with
temperature decrements (“touchdown mode”) in which the annealing temperature was
begun at 62°C (higher than the recommended 55°C) for four cycles to facilitate the
specific annealing of the mutant primers, with the annealing temperature then decreased
4°C every four cycles until the annealing temperature of 50°C was reached for the final
six cycles (18 total cycles): 4 cycles at 62°C, 4 cycles at 58°C, 4 cycles at 54°C, and 6
cycles at 50°C. Following the 1 hour digestion of all reactions with Dpn1 at 37°C to
remove the residual wild type template from the reaction mixture, 50µL of XL1-Blue
supercompetent cells (provided in kit) were transformed with 1µL of the mutagenesis
PCR product and plated on LB agar with kanamycin (25µg/mL) selection. Individual
colonies from each mutagenesis reaction were grown, plasmid DNA purified from each
clone, and constructs sequenced using the M13R primer to verify that the correct
mutation was present with no other alterations in the DNA sequence.
The sequence-verified clones were then subjected to double digestion (like the
wild type pCR-Blunt-MLL2 CXXC construct above) using AatII and BamHI (NEB or
Fermentas FastDigest®) restriction enzymes in 40µL reaction volumes and ~5ng of
mutant MLL2 CXXC plasmid DNA per reaction. The digested, mutant MLL2 CXXC
constructs were gel purified and swapped into the pMCS5-5’MLL/MLL2(wt. CXXC +
‘post-CXXC’) construct (Table 2, F) using the AatII and BamHI restriction sites as was
done to exchange the wild type MLL2 CXXC sequence above. The mutant constructs
were subsequently subcloned into the larger fusion construct like the wild type version
using the same restriction enzyme sites and three-way ligation technique described above.
The constructs were sequenced at each step to verify the accuracy of the inserts including
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the presence of the desired mutation(s) and the maintenance of the necessary reading
frame through all restriction site junctures that make up the final pMSCVneoMLL/MLL2(mt CXXC + ‘post-CXXC’)-AF9 constructs (Table 2, I).
Production of Retrovirus
Plasmid DNA of the pMSCVneo (negative control), pMSCVneo-MLL-AF9
(positive control), and pMSCV-MLL/MLL2(wt./mt. CXXC ± ‘post-CXXC’)-AF9
constructs was purified from 250mL overnight bacterial cultures in LB selection media
using the Plasmid Purification Midi Kit (Qiagen, #12145). Centrifugation steps were
performed using a high-capacity, floor model centrifuge (Beckman, #J2-MI) and the
corresponding JA-10 and JA-20 rotors. The final DNA pellet was dissolved in 10mM
Tris, pH 8.0 and the concentration determined using a NanoDrop 2000.
Five plates of PhoenixTM Ecotropic virus-packaging cells (Allele Biotech. &
Pharm. Inc., #ABP-RVC-10002) were plated at 3x106 cells per 10cm2 dish for each
construct on Day 1. These cells were allowed to grow overnight in HyClone®
Dulbecco’s Modified Eagle’s Medium, DMEM/High Glucose (Thermo Scientific,
#SH30022.01), with 1% penicillin/streptomycin and 10% fetal bovine serum
(DMEM/1%P/S/10%FBS) at 37°C in a Heraeus incubator to achieve 50-60% confluence
by the time of transfection on Day 2. Each plate of cells was transfected with 25µg
plasmid DNA using the calcium phosphate CalPhosTM Mammalian Transfection Kit
(ClonTech, #631312). Cells were incubated overnight at 37°C in 5% CO2 with culture
media containing the DNA plasmid and calcium phosphate complexes. This calcium
phosphate-containing media was removed after ~16 hours on Day 3 and replaced with
fresh media lacking calcium phosphate. The cultures were transferred to 32°C and 5%

44
CO2 and the virus-containing media was collected from and replaced for each plate at 24hour intervals for two days (Days 4 and 5). The media from plates containing identical
constructs was pooled together on Day 5. The retroviral packaging cells were harvested
in 1x sterile phosphate buffered saline (PBS) for detection of stable fusion protein
production via Western Blot at a later date. The cells were pelleted in aliquots of 107
cells in a Beckman GS-6KR centrifuge at 1500 rpm and 10°C and snap frozen on dry ice
for storage at -80°C.
The pooled media containing the virus particles of each construct type was added
to a primed Centricon® Plus-70 filter (Millipore, #UFC10008) for concentrating the virus
supernatant. The viral media was filtered via centrifugation at 1640rpm and 25°C in a
Beckman GS-6KR centrifuge for 1.5-2 hours until all but 1-2mL had entered the filter.
The filters were inverted onto a collection reservoir and centrifuged in a benchtop
centrifuge (Sorvall, #RT6000B) for 10 minutes at 3000rpm and 25°C to release the
concentrated media containing the virus particles. The volume of the virus supernatant
was adjusted to a final 7x virus concentration by adding the appropriate volume of
HyClone® Roswell Park Memorial Institute (RPMI)-1640 media (Thermo Scientific,
#SH30027.01) with 1% P/S and 20% FBS. The concentrated supernatants were
separated into aliquots of 750µL, snap frozen on dry ice, and stored at -80°C.
Determination of Retrovirus Titer
The concentration of retrovirus was determined by infecting Rat1a fibroblast cells
with serially diluted virus supernatant and was measured by the ability of the cells to
form colonies in the presence of antibiotic selection. In this manner, colony formation
would indicate effective viral uptake and expression of the desired plasmid through
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acquired resistance to the antibiotic. A high number of colony forming units (CFUs)
corresponds with a high virus titer, especially when the high number of colonies is
formed in a well where the virus had been present in a low dilution. To measure the virus
titer, a standardized number of 85,000 Rat1a cells was plated in each well of a 6-well
plate (i.e. 1 6-well plate per retroviral construct), and the cells were allowed to grow
overnight at 37°C and 5% CO2 in DMEM/1%P/S/10%FBS.

A series of 10-fold virus

dilutions were made ranging from 10-2 to 10-6 in 1-mL volumes of DMEM/10%FBS with
16µg/mL polybrene (without the 1% P/S that was previously used). Polybrene, a
positively charged polymer, was added to the media to increase viral uptake efficiency by
helping to neutralize repulsive negative charges on the cell surfaces. The day-old culture
media from each well was replaced with this 1-mL of fresh media containing a diluted
virus: 10-2, 10-3, 10-4, 10-5, 10-6, or 1mL of polybrene-containing media with no virus.
The cultures were returned to 37°C for 4 hours to allow the cells to take up the virus after
which time 1ml of fresh DMEM/10%FBS without polybrene or P/S was added to each
well. The cultures were allowed to grow overnight at 37°C and 5% CO2. The following
morning, the media was replaced with 2mL of fresh DMEM/10%FBS, and 1 mg/mL of
HyClone® G418 antibiotic (Thermo Scientific, #SV30069.1) was added to each well to
select for Rat1a cells which took up the retrovirus and express the neomycin resistance
gene from the pMSCV constructs. Cultures were incubated at 37°C and 5% CO2 for
twelve days while changing the media as needed (usually every fourth day) and
maintaining the G418 antibiotic selection for the duration of the culture period. At the
end of the twelve days of selection, the media was removed from each well, and
methylene blue dye (1.7µg/mL in methanol) was added to each well to stain Rat1a
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colonies. The number of colonies in each well was counted as a colony forming unit
(CFU), and the virus titer for each construct was determined by the average number
colonies in each well of serially diluted virus.
Isolation of murine bone marrow cells
Six- to twelve-week old C57Bl/6, male mice (Taconic, #C57BL/6NTac) were
euthanized via CO2 inhalation. The femurs and tibias were collected and cleaned using
sterile surgical technique and placed in RPMI/2%FBS. The marrow cavities of the bones
were flushed into a culture dish with this RPMI/2%FBS using a 1mL, 25-gauge,
EclipseTM Injection Needle with Luer-LokTM Syringe (BD, #305780). The cells were
pelleted by centrifugation (Beckman GS-6KR) at 1500rpm and 4°C for 5 minutes and
resuspended in sterile, chilled 1x red cell lysis buffer (10x red cell lysis buffer: 1.55M
NH4Cl, 120mM NaHCO3, 1.3mM EDTA). Resuspended cells were incubated at room
temperature with periodic mixing for about 5 minutes until the red tint was no longer
visible. This mixture was then passed through a nylon 70µm cell strainer (BD Falcon,
#352350) to remove any debris. The remaining cells (the viable white blood cells from
the bone marrow) were pelleted, resuspended in sterile 1x PBS, and counted using a
hemocytometer counting chamber (Hausser Scientific, #3200) and 0.4% trypan blue stain
(Gibco, #15250-061). The mice were handled and housed in compliance with LUMC
Comparative Medicine Facility and I.A.C.U.C. policies.
CD117 positive selection of murine bone marrow progenitor cells
The isolated white blood cells from the mouse bone marrow underwent selection
for the c-kit (CD117) cell surface marker using the EasySep® Mouse CD117 Positive
Selection Kit (Stem Cell Technologies, #18757). Specifically, isolated white blood cells
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were resuspended in sterile PBS/2%FBS to a final concentration of 1x10 cells/mL in a
round-bottom Fisherbrand® 12x75mm polypropylene culture tube (Fisher, #14-956-10).
The CD117 PE Labeling Reagent (containing c-kit antibody) was added to the cells at
50µL per 1-mL volume of cells, mixed, and allowed to incubate for 15 minutes at room
temperature. Next, the EasySep® PE Selection cocktail containing a bispecific
tetrameric antibody complex (recognizing both c-kit/CD117 and dextran) was added at
70µL per 1-mL volume of cells, mixed, and incubated at room temperature for 15
minutes. Resuspended Magnetic Nanoparticles coated with dextran were then added at
50µL per 1-mL volume of cells, mixed, and incubated at room temperature for 10
minutes. The suspension volume was brought up to 2.5mL by adding PBS/2%FBS and
the tube was set inside the EasySep® Magnet (Stem Cell Technologies, #18000) without
the tube cap and was incubated for 5 minutes at room temperate to magnetically separate
the c-kit positive bone marrow progenitor cells. Next, while the tube remained inside the
magnet, the supernatant was smoothly decanted in a single motion leaving the
magnetically-separated c-kit positive cells within the tube. The tube was removed from
the magnet, and the cells were washed with 2.5mL PBS/2%FBS and, again, incubated
within the magnet without the tube cap for 5 minutes. This wash and incubation step was
repeated for a total of four separations. The washed cells, having been positively selected
based on c-kit/CD117 cell-surface expression, were counted and resuspended in
RPMI/10%FBS/1%P/S which was supplemented with 0.05 mM β-mercaptoethanol,
50ng/mL SCF, 10ng/mL IL-3, and 10ng/mL IL-6 at a final concentration of 106 cells/mL.
The cells were incubated in a humidified round-bottom, 96-well plate overnight at 37°C
and 5% CO2.
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Retroviral transduction of c-kit positive bone marrow progenitor cells
The spinoculation method for was used for transducing c-kit positive bone
marrow progenitor cells. 30,000 cells which had been selected on the previous day were
added to a mixture of 750µL of concentrated viral supernatant, 7.5mM HyClone®
HEPES solution (Thermo Scientific, #SH30237.01), 4µg/mL polybrene (also called
hexadimethrine bromide from Sigma, #H9268), and RPMI/10%FBS to a final volume of
5mL in a conical 12x75mm culture tube (VWR, #60818-102). (Two aliquots—1.5mL
total—of virus supernatant were used for the V975P and V982T constructs since these
retroviruses had lower yields in the 104 CFU range. The total spinoculation volume was
10mL for these constructs, and the volumes of the other components were doubled
accordingly to maintain the concentrations. Spinoculation with the empty vector,
pMSCVneo retrovirus was conducted using half a volume of supernatant, 375µL, in a
total volume of 1mL.) The spinoculation mixture was briefly mixed by vortexing and
then subjected to centrifugation (Beckman GS-6KR) at 3000rpm and 33°C for 4 hours.
Following spinoculation, the supernatant was removed, and the cells were resuspended in
200µL of fresh RPMI/10%FBS/1%P/S supplemented with 0.05mM β-mercaptoethanol,
50ng/mL SCF, 10ng/mL IL-3, and 10ng/mL IL-6. The cells were incubated in a
humidified round-bottom, 96-well plate overnight at 37°C and 5% CO2. The following
day, the cells underwent a second spinoculation using the same volumes and components
as the previous day. After this second spinoculation, the retrovirally transduced cells
were plated in methylcellulose as described below.
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Methylcellulose Colony Assay
Transduced c-kit positive hematopoietic progenitor cells were plated at 1,00010,000 cells per 35mm culture plate depending on the observed transformation capacities
of the various retroviral fusion constructs. Cells were added to MethoCult® M3234
Methylcellulose Medium for Mouse Cells (Stem Cell Technologies, #03234) which had
been supplemented with glutamine, 50ng/mL SCF, 10ng/mL IL-3, 10ng/mL IL-6, and
10ng/mL GM-CSF. For the first round of plating immediately following viral
transduction, 1.25mg/mL of HyClone® G418 antibiotic (Thermo Scientific,
#SV30069.1) was added to the semi-solid media to select for those progenitor cells which
were effectively transduced with the retrovirus and stably expressing the plasmid of
interest. This mixture of cells, methylcellulose, cytokines, and antibiotic were thoroughly
vortexed to generate a homogeneous culture. A 16-gauge, 1.5” blunt-end needle (Popper,
#SBN16X1-1/2) was added to a 3ml syringe with Luer-LokTM Tip (BD, #309657) and
both were primed by flushing with culture medium to remove all residual air. 1.1mL of
culture medium containing the cell/methylcellulose/cytokine mixture ± antibiotic was
added to each of two tissue culture-treated 35-mm dishes (CytoOne, #CC7682-3340).
The plates were gently rocked to evenly distribute the culture media throughout the plate.
The smaller 35-mm dishes were added to a larger humidified chamber and incubated at
37°C for six days to allow for colony formation.
At the end of 6-days, the number of colonies on each plate was counted, reported
as colony forming units (CFUs), and all CFUs were normalized to an initial number of
10,000 cells plated per dish. Each construct had two plates of cells grown in parallel, and
the number of CFUs was averaged between these two plates for the final, normalized
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CFU count of each round. Pictures of representative colony morphology were taken on a
Leica DMIL microscope at 4x objective magnification with a Canon PowerShot S40
digital camera and acquired with Canon Utilities ZoomBrowser EX v3.2 software.
Cells from each round of plating were harvested by diluting the semi-solid
methylcellulose media in sterile PBS and transferring to a conical tube for centrifugation.
The number of viable cells was counted on a hemocytometer by trypan blue staining and
reported as a total cell number normalized to 10,000 cells initially plated. 1,000-10,000
cells transduced with each construct were re-plated in methylcellulose media without
G418 antibiotic for subsequent rounds (at least 3) to determine replating and proliferative
potential of each fusion construct. Remaining cells from each round were frozen for
viability in bone marrow freezing media (RPMI/47.5%FBS/7.5%DMSO) at a rate of 1°C/minute in an isopropanol Cryo 1°C Freezing container (Nalgene, #5100).
Colony assays for hydrogen peroxide (Sigma, #U8879-50TAB), parthenolide
(Sigma, #P0667), and spermine nonoate (Sigma, #S150) toxicity assays were performed
in the same manner as described above using MLL-AF9 and MLL(C1188A)-AF9 cells
that had been previously transformed11. These cells were treated overnight with varying
concentrations of compound prior to being plated in methylcellulose at 1,000-2,000 cells
per plate and incubated for 5-7 days.
For the colony assays with varying oxygen concentrations, untreated MLL-AF9
and MLL(C1188A)-AF9 cells were plated in methylcellulose with the appropriate
cytokines in equal numbers and placed inside an airtight, humidified, modular incubator
chamber (Billups-Rothenberg, #MIC-101). (Cultures grown under 21% O2 were not
placed in an airtight chamber and were instead simply placed in an incubator containing
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room air: 21% O2/5% CO2/74% N2) The chamber was then flushed with air containing
various oxygen concentrations (1, 5, or 60% O2 with 5% CO2 and balanced by N2 from
MedOx, #G1803961, G1811061, and G1806151, respectively) using a Harris two-stage
regulator, and the gases were allowed to equilibrate for 1-2 hours before the chambers
were flushed with the same gas for a second time to ensure a stable oxygen concentration.
Air chambers were placed in a 37°C incubator for 5-6 days to allow for cell growth and
colony formation. Following this incubation period, colony numbers were analyzed and
compared.
Cytospin for cell morphology
Approximately 50,000 cells were suspended in less than 400µL and fixed to
coated Shandon Cytoslides® (Thermo Scientific, #5991056) using Single Cytology
Funnels (Fisher Scientific, #10-354) and centrifuged in a Cytospin 4 (Thermo Scientific)
at 1000rpm for 4 minutes with medium acceleration. Cytopsun slides were allowed to air
dry overnight at room temperature. Cells were stained with HEMA-FAST 3 Step Stain
(Exaxol Chemical Corp., #SH6427G, #SH6427R, #SH6427B). Cover slips were affixed
to the slides with Richard-Allen Scientific CytosealTM 60 (Thermo Scientific, #8310-4) to
preserve the integrity of the samples. Photos of cell morphology were obtained on an
Olympus Provis AX80 microscope at 40x objective magnification using a multi control
unit (Olympus, #U-MCB) and a Q-Imaging Retiga-4000R digital camera (Model RET4000R-F-M-12-C). Images were acquired using the QCapture Plug-In and Adobe
Photoshop v6.0 software. Scale bars were determined using a stage micrometer
(Graticules LTD) with millimeter gradations (LUMC Core Imaging Facility).
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RNA Isolation
RNA from frozen, Round 1, colony assay cells (8.5x104 to 5.82x106 cells) was
isolated with TRI Reagent® (Sigma, #T9424). Specifically, the frozen cells were quickly
thawed at 37°C and washed with pre-warmed RPMI media to remove DMSO. The
washed cells were lysed in 500µL TRI Reagent® for 5 minutes at room temperature.
100µL of chloroform was added to the mixture was shaken, and incubated at room
temperature for 10 minutes after which point the solution was centrifuged at 12,000xg
and 4°C for 15 minutes to separate mixture into three distinct layers. The upper, clear
aqueous layer containing the RNA was transferred to a new tube, being careful not to
transfer the precipitated DNA from the adjacent, middle layer. 250µL isopropanol was
added to the isolated aqueous layer and incubated at room temperature for 10 minutes.
The solution was centrifuged at 12,000xg and 4°C for 10 minutes. The supernatant was
discarded leaving behind the precipitated RNA pellet which was washed with 1mL 75%
molecular-grade ethanol (Absolute 200 Proof, AAPER Alcohol, #02A02UA) and
resuspended by vortexing. After centrifugation at 7,500xg and 4°C for 5 minutes, the
supernatant was removed, and the pellet was air dried for ~10 minutes. The RNA pellet
was dissolved in RNase-free dH2O (DEPC-treated dH2O, de-gassed, and autoclaved).
The concentration of the total isolated RNA was measured using the NanoDrop 2000.
Generation of cDNA
The isolated RNA from Round 1 colony assay cells was reverse transcribed into
cDNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
#4368814). 10µL of RNA from each construct (not exceeding 2µg of RNA) was added
to reaction mixtures containing 10x RT Buffer, 25x dNTP Mix, and 10x RT Random
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TM

Primers with or without (control to detect DNA contamination) MultiScribe

Reverse

Transcriptase according to the supplier’s protocol. The cDNA was generated via RTPCR in a PCR Express Thermal Cycler using the cycling parameters described in the kit.
Quantitative RT-PCR
Quantitative Reverse-Transcriptase PCR—or Real Time PCR—was used to
determine gene expression levels of Hoxa9 bone marrow progenitor cells from Round 1
of the methylcellulose colony assay. The qRT-PCR reaction mixture was prepared using
the TaqMan® Gene Expression Assay kit (Applied Biosystems). Each 20µL qRT-PCR
reaction mixture was performed in triplicate with 4µL RT-PCR product (either cDNA or
the no RT control products), 10µL 2x Gene Expression Master Mix (AB, #4324018), and
1µL of either 20x Gene Expression Assay for Hprt1 (endogenous control,
Mm01545399_m1) or Hoxa9 (Mm00439364_m1). Triplicate samples (including, nontemplate controls) were distributed among the wells of a 0.2mL Thin Wall, Non-Skirted,
96-well PCR plate (Dot Scientific Inc., #650-PCR) and sealed with ThermalSeal RTTM
Optically Transparent Sealing Film (Dot Scientific Inc., #TSRT2100). The qRT-PCR
reaction was run on an Applied Biosystems 7300 Real-Time PCR System using the
following cycling parameters: 50°C for 2 minutes, 95°C for 10 minutes, and then 40
cycles alternating between 95°C for 15 seconds and 60°C for 1min. The data was
acquired with 7300 System software (Applied Biosystems) and analyzed using the 2-ΔΔCt
method159. The relative Hoxa9 expression levels were normalized to endogenous Hprt1
expression levels.
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Generation of GST fusion repression domain constructs
The nucleotide sequences encoding the MLL and MLL1/2 repression domains
(RD) were PCR amplified from pMSCV-MLL-AF9 and pMSCV-MLL/MLL2(wt.
CXXC + ‘post-CXXC’)-AF9 constructs, respectively, using the cloning primer sequences
listed Table 3. The forward primer contains a NruI restriction site which forms a blunt
end when digested with NruI and could subsequently be ligated to the EcoRV blunt end
of the GST expression vector, pGS-21a (GenScript, #SD0121-10ug). The reverse
primers for cloning the RD constructs contain the SalI site that was used previously. The
RD sequences were PCR-amplified using a Phusion® high-fidelity DNA polymerase
(Finnzymes/NEB, #F530S), were ligated into the pCR-Blunt holding vector, and
transformed into OneShot® Top10 chemically competent E.coli using the Zero Blunt®
PCR Cloning kit described previously. The accuracy of the amplified RDs was verified
by sequencing with the M13R primer.
Then, the purified pCR-Blunt-MLL-RD or –MLL1/2 -RD constructs were
digested simultaneously with NruI (NEB) and SalI (NEB) in a 50µL reaction volume
containing NEB Buffer #3 for 1.5 hours at 37°C. The digested RD fragments were
separated by electrophoresis on a 1% agarose gel (20 minutes at 90V) and gel purified.
The empty GST expression vector, pGS-21a, was digested with EcoRV (Amersham) and
SalI (NEB) in a 50µL reaction volume containing NEB Buffer #3 for 2 hours at 37°C.
This digest reaction was heat-inactivated at 65°C for 15 minutes and 2µL of CIP (NEB)
was added to prevent self-ligation of the linearized vector which was subsequently
purified through gel extraction. The digested RD constructs were ligated with the
linearized pGS-21a GST expression vector in a 10µL reaction with T4 DNA ligase
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(Fermentas) for 1 hour at 16°C to generate the wild type repression domain constructs of
pGS21a-MLL-RD and pGS21a-MLL1/2-RD (Table 2, J). The inserts encoding the RDs
were sequence-verified using the universal T7 terminator primer.
The sequences encoding the mutant MLL2 CXXC domains (A964R, R970P,
LRVQ973-6QVPE, V1001K, and R1011M) were swapped into the pGS21a-MLL1/2
repression domain construct in exchange for the wild type nucleotide sequence of MLL2
CXXC domain using the same unique AatII and BamHI restriction sites as were
previously used to swap these domains during the cloning of the AF9 fusion constructs.
The sequences of each mutant repression domain were verified using the T7 terminator
primer.
Bacterial over-expression of GST fusion MLL- and MLL1/2 repression
domain constructs
The pGS21a repression domain constructs were transformed into chemically
competent BL21(DE)pLysS cells (Novagen, #69451-3) to maximize expression of the
GST fusion constructs. Briefly, 1µL of plasmid DNA was added to 20µL of thawed
BL21(DE)pLysS cells in a 15-mL round bottom culture tube on ice and incubated for 5
minutes. Cells were heat shocked at 42°C for 30 seconds and transferred back to ice for 2
minutes before adding 80µL of room temperature S.O.C. medium and shaking at 37°C
and 225rpm for 1 hour. Transformed cells were plated on LB agar plates for ampicillin
selection and grown overnight to allow bacterial colonies to form.
A freshly plated colony of BL21(DE)pLysS cells expressing each pGS21a-MLL
or –MLL1/2(wt./mt CXXC + ‘post-CXXC’) repression domain construct was picked and
used to inoculate 100mL of LB broth with ampicillin (100µg/mL) and chloramphenicol
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(15µg/mL, Sigma, #C0378) overnight in a shaker at 225rpm and 37°C. The following
morning, the 100-mL cultures were diluted 1:10 by adding 900mL LB Broth with
ampicillin but no chloramphenicol. The cultures were grown for about 3 hours until an
O.D.600 of at least 0.5 was reached (Beckman DU® 530 Life Science UV/Vis
Spectrophotometer). Protein production was then induced by adding 1mM IPTG
(Research Products Int. Corp., #367-93-1) for 3 hours with continued shaking of the
cultures at 225rpm and 37°C. Cultures were then pelleted at 6000xg in a JA-10 rotor of
the high capacity Beckman J2-MI centrifuge, and the pellets were frozen at -20°C.
Purification of GST fusion repression domain constructs
Frozen bacterial pellets were thawed on ice and resuspended in 60mL Lysis
Buffer (50mM Tris, pH 8.0, 300mM NaCl, 1mM EDTA) with protease inhibitor cocktail
(1 Roche tablet, #04 693 132 001, per 50mL buffer) and PMSF (1:1000). Lysozyme
(1mg/mL) was added directly from powder to the resuspension mix followed by Triton
X-100 to a final 1% concentration. The lysis mixture was inverted frequently while
incubating on ice for 5 minutes. The lysate was then sonicated two times for 20 seconds
while on ice with the Output Control set to 5 (Branson Sonifier 250). The lysate was
transferred to centrifugation tubes and spun at 9000rpm and 4°C for 30 minutes in the
JA-20 rotor of the Beckman J2-MI centrifuge. The supernatant was transferred to a fresh
tube and 500µL of a 50% slurry of swollen and washed Glutathione-agarose beads
(Sigma, #CL-4B) was added to the supernatant. The solution was incubated end-overend at low to medium speed on a Rugged Rotor (Glas-Col®) at 4°C for 2 hours to allow
the Glutathione-agarose beads to bind the GST fusion constructs. The beads were then
pelleted and washed four times with cold Wash Buffer (lysis buffer including the 1%
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Triton X-100, protease inhibitors, and PMSF). Washed beads were resuspended in a
volume of this wash buffer to create a 50% slurry of beads. All steps were performed on
ice or at 4°C.
Purified GST proteins were detected by SDS-PAGE (4% stacking and 10%
resolving acrylamide gel) using the BioRad Mini-PROTEAN® 3-Cell System followed
by Coomasie staining or by Western Blot with a rabbit polyclonal anti-GST primary
antibody (Abcam, #ab19256) and an ECLTM donkey anti-rabbit secondary antibody
conjugated to Horseradish Peroxidase (GE Healthcare, #NA934V). The blot was
developed with SuperSignal® West Pico Chemiluminescent Substrate (Thermo
Scientific, #34078) and exposed to CL-XPosureTM Film (Thermo Scientific, #34090), or
the chemiluminescence was detected using a Fujifilm LAS-3000 imaging system and
Image Reader LAS-3000 software. Band intensities were analyzed with Multi Gauge
v3.0 software (Fujifilm).
In vitro transcription and translation
HDAC1 (pcDNA3-HDAC1-FLAG Glycerol Stock #562/563), HPC2 (pcDNA3T7-HPC2, Glycerol Stock #658), and PAF1 (pcDNA3-PAF1, Addgene #11059, Glycerol
Stock #1136) proteins were expressed using the TNT® T7 Coupled Reticulocyte Lysate
System (Promega, #L4610). Plasmid DNA was purified using the Midi Kit from Qiagen
to be used as the template for the IVTT reaction. The reaction components were
combined according to the supplier’s protocol using 1.0µg template DNA, the amino acid
mixture minus methionine, RNase Inhibitor (Applied Biosystems, #AM2682), and L[35S]-Methionine, aqueous solution (PerkinElmer, #NEG709A500UC) to radioactively
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label the IVTT proteins for detection via phosphorimaging. The reaction was incubated
at 30°C for 90 minutes.
5µL of each IVTT reaction mixture was electrophoresed on an SDSpolyacrylamide gel (4% stacking, 10% resolving) to compare the reaction efficiencies
before the IVTT proteins would be used for protein binding studies. The electrophoresed
gel was dried on filter paper (BioRad gel dryer, #583). The radioactive gel was exposed
to a blanked Imaging PlateTM (Fujifilm, #BAS-IIIs) for 4 to 12 hours within a Standard
BAS Cassette (Fujifilm, #2040). The signal from the Imaging PlateTM was, then,
detected with a Typhoon 8600 Variable Mode Imager and Typhoon Scanner Control v1.0
software (Molecular Dynamic Inc., Amersham) using the Storage Phosphor acquisition
mode with a pixel size of 50 microns. ImageQunat TL v2005 software (Amersham) was
used to analyze signal intensities generated by the 35S-labeled proteins.
In vitro protein binding assay
Equivalent amounts of purified GST repression domain proteins were combined
with 20 to 30µL of HDAC1, HPC2, or PAF1 IVTT reaction product depending on the
expression efficiency of the 35S-labeled protein. The binding volume was brought up to
100µL for all reactions by adding Wash Buffer (described above). GST-tagged
repression domain proteins and IVTT proteins were incubated together on an end-overend rotor at low to medium speed at 4°C for 2 hours. Beads were then washed 4 times
while on ice with chilled Wash Buffer (1mL per wash). Interacting proteins were eluted
from the beads by adding SDS loading buffer to the washed beads and boiling at 95°C for
5-10 minutes. The eluted proteins were separated by SDS-PAGE and bands were
detected as described above. Detected bands of interacting 35S-labeled IVTT proteins
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(HDAC1, HPC2, or PAF1) were quantified relative to the GST-MLL-RD binding
intensity and normalized to the amount of each GST input.
FLAG-tagged CtBP was overexpressed in 293T cells by transient transfection
using the calcium phosphate kit described previously. 48 hours after transfection, cells
were collected, pelleted, and snap frozen on dry ice in aliquots of 107 transfected cells,
and stored at -80°C. When needed, cell aliquots were thawed on ice and resuspended in
500µL IPH Buffer (50mM Tris, pH 8.0, 150mM NaCl, 5mM EDTA, 0.5% NP-40, and
protease inhibitor cocktail 1:200). The cell lysates were incubated on ice for 10 minutes
and then centrifuged at >14,000rpm and 4°C for 30 minutes. The supernatant was snap
frozen on dry ice and stored at -80°C until used in the in vitro binding study. Prior to the
binding experiments, equal amounts of each GST-tagged repression domain protein were
incubated on ice for 15 minutes with 200µL of Z’Buffer (25mM HEPES, pH 7.5,
12.5mM MgCl2, 150mM KCl, 0.1% NP-40, 20mM Tris pH 8.0), BSA (1mg/mL), PI
cocktail and PMSF (1:1000). 25µL of CtBP-FLAG-containing cell lysate was added to
each GST-repression domain protein and incubated end-over-end at low to medium speed
at 4°C for 2 hours. Glutathione beads were washed four times with 1mL chilled NETN
buffer (100mM NaCl, 1mM EDTA, 0.5% NP-40, 20mM Tris pH 8.0). Bound proteins
were eluted from the washed beads by the addition of SDS loading buffer and boiling for
5-10 minutes at 95°C. Proteins were separated by SDS-PAGE and detected by Western
Blot using a primary monoclonal mouse anti-FLAG M2 antibody (Sigma, #F3165) and a
secondary ECLTM sheep anti-mouse secondary antibody conjugated to Horseradish
Peroxidase (Amersham, #NA931V). Band intensities of CtBP were calculated relative to
the GST-MLL RD interaction and normalized to the amount of GST inputs.
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MTT Assay
The MTT assay was used as a measure of cell proliferation and viability. The
MLL-AF9 and MLL(C1188A)-AF9 transformed cell lines had previously been generated
in our lab by Laurie Risner, PhD, and were cultured in RPMI/20%FBS/1%P/S with
50ng/mL SCF, 10ng/mL IL-3, 10ng/mL IL-6, and 10ng/mL GM-CSF 11. The optimal
cell numbers for the MTT assay were determined by serially diluting the cells (0 to
400,000 cells) in 100µL of media per well of a 96-well flat-bottom plate in triplicate.
MTT reagent, thiazolyl blue tetrazolium bromide (Sigma, #M5655), was added to cells at
a final concentration of 0.5 mg/mL and incubated at 37°C for 6 hours after which purple
formazan crystals were visible in the cultures. Crystals were dissolved with the addition
of 100µL of solubilization solution (10% Triton X-100, 0.1mM HCl, isopropanol to
volume). Absorbance of the reaction mix was measured at a wavelength of 550nm on a
fluorescent plate reader and analyzed with Omega software. For toxicity assays, 30,000
MLL-AF9 or MLL(C1188A)-AF9 cells were pre-treated with varying doses of hydrogen
peroxide (Sigma, #U8879-50TAB), parthenolide (Sigma, #P0667), or spermine nonoate
(Sigma, #S150) and incubated overnight in a 96-well plate at 37°C and 5% CO2. The
following morning, MTT reagent was added as above. All MTT reactions were set up
using a multi-channel pipet and measured in triplicate.
Statistical Analysis
The data presented represent the averages of multiple experiments with error bars
representing one standard deviation unless otherwise noted. Statistical significance,
where calculated, was determined by the two-tailed Student’s T-test for independent
variables with the threshold for significance set at p < 0.05.

CHAPTER 4
RESULTS
Aim 1: Determine how differences in the MLL CXXC domain and the MLL2
CXXC domain contribute to different transformation capacities of MLL/MLL2AF9 fusion proteins
Comparison of co-repressor and co-activator protein interactions with MLL and
MLL1/2 repression domains
The MLL repression domain (amino acids 1100-1400) has previously been shown
to interact with transcriptional co-repressor proteins (HDAC1, HPC2, and CtBP) and coactivator, PAF1, but it is unknown if the closely related homolog, MLL2 (also known as
MLL4), interacts with these proteins. A Glutathione-S-transferase (GST) pull-down
assay was conducted to determine if these cofactors also interact with residues of the
MLL2 repression domain. A GST-tagged construct was generated in which the ‘preCXXC’ residues of MLL (amino acids 1100-1151) were fused to the CXXC and ‘postCXXC’ residues of MLL2 (amino acids 958-1172) which align with the MLL repression
domain (Figure 6A). This MLL 1/2 repression domain construct was expressed in
bacteria and purified with immobilized glutathione-agarose. Equal amounts of
immobilized GST protein were incubated with cofactor proteins which were expressed by
in vitro transcription and translation, IVTT, (HDAC1, HPC2, or PAF1) or by transient
transfection in 293T cells (CtBP). Following incubation and washing, bound proteins
were electrophoresed on a SDS-PAGE gel, and the interactions were detected by
phosphorimaging (35S-labeled HDAC1 and HPC2) or Western blot (FLAG-tagged CtBP).
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Figure 7. HDAC1 binds to both the MLL repression domain and
the equivalent MLL1/2 repression domain.
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(A) GST fusion constructs generated for pulldown assays (not drawn to scale).
GST—isolated GST domain (negative control); MLL—MLL repression domain
(amino acids 1100-1400) fused to GST; MLL 1/2—chimeric repression domain
consisting of MLL ‘pre-CXXC’ residues (MLL amino acids 1100-1151) and the
MLL2 CXXC and ‘post-CXXC’ residues aligning with the MLL repression domain
(MLL2 amino acids 958-1172); mt. MLL 1/2—chimeric MLL 1/2 repression domain
with amino acid substitution(s) which restore MLL2 CXXC domain residue to
corresponding MLL residue.
(B) Phosphorimaging analysis of 4-5 independent GST pulldown assays showing
relative 35S-labeled HDAC1 binding.
(Mean ± 1 S.D.)
A representative
phosphorimage is shown below along with a Western Blot (bottom) of GST inputs.
Detected bands of interacting HDAC1 were set relative to the intensity of the MLL
band and normalized to the amount of each input GST protein. (p > 0.05 by Student’s
T-test for all interactions compared to MLL1/2 binding, *except GST control.)
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Figure 9. CtBP binds to both the MLL repression domain and the
equivalent MLL1/2 repression domain.
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HDAC1, HPC2, and CtBP all bound specifically to the MLL 1/2 repression domain and
the wild type MLL repression domain (positive control) with minimal or no binding to
GST alone (negative control) (Figures 7-9). HDAC1 and CtBP showed similar levels of
binding to the repression domain constructs containing either the wild type MLL or the
wild type MLL 2 CXXC domain (Figures 7 and 9). In three independent experiments,
however, HPC2 showed increased binding to the MLL 1/2 repression domain construct
compared to the MLL repression domain (Figure 8). When the HPC2 binding results
were averaged from each experiment, though, the dynamic range of the binding
intensities from individual experiments prevented this difference of HPC2 binding to the
MLL and MLL1/2 RDs from achieving statistical significance (p > 0.05 by Student’s Ttest for all interactions).
Determination of residues within the CXXC domain that alter co-repressor binding
I next wanted to determine if residues unique to MLL —when introduced into the
MLL2 CXXC domain—would reduce or enhance binding of co-repressor proteins
compared to binding of the wild type MLL2 CXXC domain. To test the role of specific
residues on protein binding, five constructs were generated in which amino acid
substitutions were introduced into the MLL2 CXXC domain to convert this domain into
the MLL amino acid sequence at each site: A964R, R970P, LRVQ973-6QVPE, V1001K,
and R1011M (Figure 6A). (These specific residues were chosen for these binding assays
based on the results of in vitro transformation and Hoxa9 expression shown later in the
results: Figure 16) Interaction of the co-repressors with these mutant MLL2 CXXC
domain constructs was performed out in the same manner as with the wild type constructs
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above. HDAC1, HPC2, and CtBP were still able to interact with each of the hybrid MLL
1/2 constructs (Figures 7-9). However, the substitution of some MLL amino acids into
the MLL2 CXXC domain did alter the relative binding intensities of these proteins
compared to the wild type MLL or MLL2 CXXC domain-containing constructs.
Specifically, the R970P and R1011M substitutions both showed decreased binding of
HDAC1 compared to the wild type MLL CXXC domain. Additionally, the V1001K
substitution reduced HPC2 binding from the wild type MLL1/2 domain levels toward the
lower binding levels of the wild type MLL domain. The differences in binding
intensities, however, were not determined to be statistically significant (p < 0.05 by
Student’s T-test).
Comparison of co-activator PAF1 binding to residues of the MLL and MLL2 CXXC
domains
The PAF1 subunit of the polymerase associated factor complex was recently
shown to interact directly with the N-terminus of MLL through the residues which flank
the CXXC domain in a DNA-independent manner10. Muntean et al showed that the
interaction of PAF1 with an MLL fusion enhances transcription of leukemogenic target
genes like Hoxa9 and Meis110. Simultaneously, work by Milne et al showed that
mutation of Arg1153 to alanine within the MLL CXXC significantly decreases binding of
PAF1 to the first half of the MLL repression domain (amino acids 1101-1250) and also
decreases expression of Hoxa99. The authors also showed that the residues of MLL2
which align with the first half of the MLL repression domain are unable to bind to PAF1.
Taken together, these data suggest there are critical differences between MLL and MLL2
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Figure 10. PAF1 binds to both the MLL repression domain and the
equivalent MLL1/2 repression domain.

200
150
100
50
0

*
GST

GST
35S

MLL

MLL

MLL1/2

MLL 1/2

A964R

A964R

R970P

R970P

LRVQ973LRVQ973V1001K
R1011M
V1001K R1011M
6QVPE
6QVPE

1%

t
pu
In

PAF1

GST Input

Average phosphorimaging analysis from three independent GST pulldown
assays showing relative 35S-labeled PAF1 binding.
A representative
phosphorimage is shown below along with a Western Blot (bottom) of GST
inputs (Mean ± 1 S.D.). Results are presented relative to MLL binding intensity
and normalized to input GST proteins. (p > 0.05 by Student’s T-test for all
interactions compared to MLL1/2 binding, *except GST control.)

68
within the CXXC domain and/or repression domain which affect the interaction of PAF1
and recruitment of transcriptional activating complexes to MLL target genes.
To better understand the role of specific residues within the MLL CXXC domain, PAF1
binding with the MLL, MLL 1/2, and mutant MLL 1/2 repression domain constructs was
compared in the same GST pull-down assay as described above.

35

S-labeled PAF1

directly interacted to the same degree with repression domain constructs containing both
the MLL and the MLL2 CXXC domains. Introduction of MLL residues (A964R, R970P,
LRVQ973-6QVPE, V1001K, or R1011M) into the MLL2 CXXC domain did not
enhance or diminish PAF1 binding suggesting that the residues of the MLL and MLL2
CXXC domains do not show differential binding for PAF1 (Figure 10).
Functional comparison of the capacity of MLL and MLL2 CXXC domain
residues to transform bone marrow progenitor cells in vitro
A previous study by Bach et al showed that introduction of both the MLL CXXC
domain and ‘post-CXXC’ domain were necessary to confer a transforming capacity to an
artificial MLL2-ENL fusion protein suggesting that there are critical residues within this
region of MLL that are required for the oncogenic function of a MLL fusion protein7.
Sequence alignment of the MLL and MLL2 CXXC domains shows conservation of the
structural zinc-coordinating cysteines and the KFGG motif which are necessary for
proper domain folding and recognition of non-methylated CpG DNA targets suggesting
that other residue within the CXXC domain must account for the observed functional
differences (Figure 12A)143, 160.
In order to understand the critical role of specific amino acids within the CXXC
domain, a chimeric fusion protein was generated in which the CXXC domain of MLL2
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Figure
Figure11.
7. The MLL2 CXXC domain can transform primary bone
marrow cells when swapped into a MLL-AF9 fusion protein.
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was exchanged for that of MLL in the context of the well-studied MLL-AF9 fusion
protein. This synthetic MLL/MLL2(CXXC)-AF9 fusion was able to transform primary
hematopoietic cells in an in vitro colony assay in which a large number of tight colonies
were formed in the third round of plating (Figure 11). These colonies were comprised of
blast-like cells similar to those of MLL-AF9 cells. Quantitative RT-PCR showed
increased levels of Hoxa9 compared to the negative control (MSCV-transduced) cells,
although the expression levels were lower than that of MLL-AF9 cells (p < 0.01 by
Student’s T-test). The ability of the MLL2 CXXC domain to transform bone marrow
progenitor cells suggests that MLL2 retains some important residues within the CXXC
domain that are also present in MLL and are able to contribute to a transforming capacity
of the chimeric protein.
In order to be able to study the gain-of-function effects of individual CXXC
domain residues, I needed to generate another fusion construct which had lower
transforming potency. A chimeric fusion protein was cloned in which the ‘post CXXC’
residues of MLL2 were swapped into MLL-AF9 along with the MLL2 CXXC domain to
create a MLL/MLL2-AF9 fusion protein (Figure 12B). In this context, I hypothesized
that the wild type MLL/MLL2-AF9 construct—lacking the critical CXXC and ‘postCXXC’ domain residues from MLL—would be non- or minimally-transforming in vitro
and would serve as a baseline control. I further hypothesized that introduction of
individual amino acid substitutions in this context (13 positions highlighted in blue in the
sequence alignment of Figure 12) to restore the MLL sequence in the MLL2 CXXC
domain could potentially rescue the MLL-fusion-transforming function (Figure 12B). I
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Figure 12. Experimental design of in vitro colony assay.
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predicted that those MLL residues which have a critical role in the oncogenic capacity of
an MLL fusion protein would rescue transformation capacity from the baseline levels of
the wild type MLL/MLL2-AF9 cells in an in vitro methylcellulose colony assay.
Determination of titers for retroviruses expressing the fusion proteins
To express the fusion proteins in bone marrow progenitor cells, retroviruses
containing the respective fusion constructs in the MSCVneo vector were generated as
described in the methods section above. To determine the virus titer of each supernatant,
Rat1a cells were infected with serial dilutions of supernatant. After selection with G418,
the number of surviving Rat1a colonies was counted as colony forming units (CFUs) to
determine viral titers for each fusion construct (Figure 13). The virus titers ranged from
2.5x104 to 2.6x106 CFUs per milliliter of supernatant (Table 5). In order to normalize the
amount of virus used for each transduction, larger supernatant volumes of the low-titer

Table 5. Rat1a virus titers of wild type and mutant MLL/MLL2-AF9 retroviral
fusion constructs.
Retroviral Construct Virus Titer (CFUs)
MSCV
1 x 106
MLL-AF9
2 x 105
w.t. MLL/MLL2-AF9
8.5 x 105
A964R
1.4 x 106
H968Q
8.0 x 105
R970P
2.6 x 106
V975P
5.2 x 104
LRVQ973-6QVPE
1.3 x 106
V982T
2.5 x 104
P993R
7.5 x 105
T995I
2.4 x 105
V1001K
4.9 x 105
VY1001-2KM
1.2 x 106
R1011M
1.1 x 106
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Figure 13. Rat1a virus titers of MLL/MLL2-AF9 retroviral fusion constructs.
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constructs were used during spinoculation so that an effective infection reaction could
take place on the order of 105-106 CFUs per spinoculation reaction.
MLL residues introduced into the MLL/MLL2-AF9 fusion protein showed variable
ability to rescue transformation capacity in an in vitro colony assay
An in vitro colony assay was performed to determine the functional importance of
individual residues within the CXXC domain. Bone marrow progenitor cells were
isolated from C57Bl/6 mice via c-kit positive selection and were transduced with similar
amounts of either wild type or mutant MLL/MLL2-AF9 retroviral constructs. The
MSCVneo empty vector retrovirus was used as a negative control, and infection with the
well-characterized MLL-AF9 construct served as a positive control. Cells were grown in
the presence of G418 for the first round of plating to select for cells infected by retrovirus
which express the MSCVneo vector neomycin resistance gene. After the first round of
growth, colony and cell numbers were counted and then the cells were serially replated
for at least three rounds or until the cultures no longer produced colonies (Figure 12C).
The numbers of colonies and cells were quantified in the third round as a measure of selfrenewal and cell proliferation capacity, respectively. When non-transformed cells—like
those infected with MSCVneo empty vector—were grown in methylcellulose in the
presence of growth factors, the bone marrow progenitor cells were stimulated to undergo
differentiation. Eventually, the cells lost their proliferative capacity forming fewer and
more diffuse colonies in early re-plating and failed to form any colonies by Round 3
(Figures 14 and 15). At the third round of plating, the non-transformed cells showed a
differentiated morphology and generated diffuse colonies (Figure 15). In contrast, cells
transduced with the highly transforming MLL-AF9 formed large numbers of dense
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colonies by Round 3 which continued to form colonies through a fifth round. The tight
colonies of MLL-AF9 transduced cells had distinct borders and are comprised of blastlike cells with large nuclei and little cytoplasm (Figure 15).
By the third round, the number of colonies formed by cells transduced by wild
type MLL/MLL2-AF9 was decreased 7-fold relative to the MLL-AF9 transformed cells,
and the total cell number was decreased 10-fold compared to the MLL-AF9 transduced
cells (Figure 14). These colonies more closely resembled those transduced with the
empty vector negative control with a more diffuse colony morphology and comprised of
cells with a differentiated morphology (Figure 15).
The thirteen individual point mutant MLL/MLL2-AF9 constructs showed variable
capacities to immortalize c-kit positive progenitor cells in vitro. No single amino acid
substitution was able to completely restore MLL/MLL2-AF9 transformation capacity
back to the levels of MLL-AF9. The measures of transformation capacity—colony
formation and cell proliferation—showed a positive correlation when MLL residues were
introduced into the MLL2 CXXC domain whereby those residues which showed higher
colony forming ability also showed an increase in total cell number (Figure 14C). The
amino acid substitutions of A964R, R970P, LRVQ973-6QVPE, and VY1001-2KM
showed the highest capacities to rescue transformation (with at least a 40% increase in
self-renewal and cell proliferation) compared to the MLL/MLL2-AF9 construct. The
substitutions of P993R, T995I, and V1001K showed intermediate (20-40%) rescue of
transformation ability while H968Q, V975P, V982T, and R1011M substitutions showed
little or no (<20%) capacity to rescue cellular self-renewal or proliferation from baseline
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levels of the wild type construct (Figure 14). Colony and cellular morphologies of these
mutant constructs also closely correlated with transformation capacities. Those
constructs causing the highest self-renewal capacity produced dense, tight colonies while
those exhibiting little capacity for self-renewal generated small numbers of primarily
diffuse colonies. The dense colonies were comprised of blast-like cells resembling MLLAF9 transformed cells while the diffuse colonies consisted of mostly differentiated cells
with large, vacuolated cytoplasm and relatively small nuclei. The constructs with
intermediate transformation capacities produced a mixture of dense and diffuse colonies
consisting of both undifferentiated and differentiated cells (Figure 15). These results
indicate that there are individual amino acids of MLL that are able to functionally restore
the phenotype of the MLL-AF9 fusion protein when introduced into the MLL2 CXXC
domain. These specific residues are critical for the transformation capacity of the CXXC
domain and the leukemogenic capacity of MLL fusion proteins.
MLL residues showed variable ability to rescue increased Hoxa9 expression when
introduced into the MLL/MLL2-AF9 fusion protein in an in vitro colony assay
Hoxa9 is a well-studied target gene of MLL. During normal hematopoiesis,

regulated transcription allows Hoxa9 expression levels to decrease as a cell differentiates
toward a more mature lineage and decreases the highly proliferative capacity of the
immature precursor cells. In leukemia cells harboring an MLL fusion protein, expression
of the Hoxa9 gene is upregulated contributing to the maintenance of an undifferentiated
state and to an unlimited capacity for proliferation and self-renewal of hematopoietic
progenitor cells. As an independent test for transformation capacity, transduced cells
from the first round of the methylcellulose colony assay were collected to measure Hoxa9
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expression. RNA from these cells was isolated and reverse transcribed to generate
cDNA. Primers for the Hoxa9 locus were then used to amplify this specific mRNA
transcript and levels were quantified via qRT-PCR.
As expected, the bone marrow progenitor cells expressing MLL-AF9 showed
high levels of Hoxa9 expression (17-fold increase) compared to the empty vector
MSCVneo (negative control). The wild type MLL/MLL2-AF9 construct expressing the
MLL2 CXXC and ‘post-CXXC’ residues showed a 10-fold reduction in Hoxa9
expression levels compared to MLL-AF9. The thirteen constructs encoding MLL amino
acid substitutions within the MLL2 CXXC domain showed variable capacities to restore
high Hoxa9 expression from the baseline levels of wild type MLL/MLL2-AF9 (Figure
16A). The expression levels of Hoxa9 positively correlated with colony formation and
cell proliferation ability in which higher transforming constructs also exhibit higher
levels of Hoxa9 expression (Figure 16B and 15C). However, in contrast to the colony
formation and cell proliferation numbers, some specific MLL amino acid substitutions
(A964R and LRVQ973-6QVPE) were able to completely restore Hoxa9 expression to
levels observed in MLL-AF9 transduced progenitor cells (p > 0.05 by Student’s T-test
compared to MLL-AF9 Hoxa9 expression levels). The MLL substitutions of R970P,
V1001K, and VY1001-2KM showed intermediate (40-60%) rescue of target gene
expression compared to the wild type level. The constructs showing weak transformation
capacity also showed low levels (<40%) of Hoxa9 expression compared to MLL-AF9:
H968Q, V975P, V982T, P993R, T995I, and R1011M. The ability of specific residues to
restore Hoxa9 expression independently verifies the functional importance of the
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Figure 16. Hoxa9 expression from Round 1 colony assay cells.
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residues that also rescued colony formation and cell proliferation ability. Those residues
which restored Hoxa9 expression levels to MLL-AF9 levels (or close to the same level)
are important residues of the MLL CXXC domain contributing to the ability of MLL
fusion proteins to transform hematopoietic progenitor cells.
Aim 2: Determine the role of Cysteine 1188 in the regulation of the MLL CXXC
domain binding to non-methylated CpG DNA
Treatment of MLL-AF9 and MLL(C1188A)-AF9 cells with agents that can modify
thiol groups
Cysteine 1188 is the only non-zinc-coordinating cysteine residue within the
CXXC domain of MLL. This residue is positioned on the DNA-binding surface of the
domain in the structure published by Cierpicki et al11. I hypothesized that posttranslational modification of the thiol side chain of Cys1188 through oxidation or
nitrosylation would inhibit the binding of the CXXC domain to its non-methylated target
DNA. Loss of DNA binding by the MLL CXXC domain would lead to decreased
transformation capacity by the MLL fusion protein in an in vitro colony assay11. In order
to test this hypothesis, MLL-AF9-transformed cells were treated with increasing amounts
of several agents that are known to oxidize (hydrogen peroxide and parthenolide) or
nitrosylate (spermine nonoate) free thiol groups. As a control, a transformed cell line
expressing mutant MLL-AF9 fusion protein was used in which the cysteine at residue
1188 was replaced with alanine11. The methyl side chain of alanine is not reactive, so
this specific amino acid position would remain unaffected by treatment with thiolreactive agents. The CXXC domain containing this C1188A mutation was shown by our
collaborators to bind to non-methylated CpG DNA with equal affinity to the wild type
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domain . This MLL(C1188A)-AF9 fusion protein was also shown by our lab to
transform bone marrow progenitor cells similar to MLL-AF911. Should oxidation or
nitrosylation modify the cysteine residue in a way that interferes with binding of the
CXXC domain to DNA, the wild type MLL-AF9 cells should show a decreased
transformation capacity compared to the mutant MLL(C1188A)-AF9 cells.
A colorimetric, cellular proliferation assay using MTT reagent was performed to
characterize potential the effects of oxidation or nitrosylation between the wild type
MLL-AF9 and mutant MLL(C1188A)-AF9 transformed cell lines. In the MTT assay,
viable cells are able to internalize the tetrazolium salt reagent (yellow color) and reduce
the compound in the mitochondria to a formazan salt product (purple color) in a manner
that is dependent on the number of cells and the metabolic activity of the viable cells in
the culture. Those cells which are viable and rapidly proliferating will reduce more
tetrazolium reagent to formazan to produce a darker purple color and result in an
increased absorbance reading at 570 nm. Wild type MLL-AF9 and mutant
MLL(C1188A)-AF9 cells were serially diluted (0 to 200,000 cells per well) in a 96-well
plate in triplicate to determine relative MTT activity of untreated cells and to determine
the optimal number of cells for each treatment assay. Independent of the number of cells,
the wild type MLL-AF9 cells showed higher absorbance readings indicative of higher
metabolic activity and greater cellular proliferation of the wild type cells compared to the
mutant MLL(C1188A)-AF9 cells (Figure 17A). 30,000 cells was determined to be
optimal for treatment as this number of cells had an absorbance reading near the middle
of the linear portion of the cell titration curve. This allowed for variation in absorbance
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Figure 17. Effect of thiol modifying agents on proliferation of MLL-AF9
versus MLL(C1188A)-AF9 transformed cells.
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(A) MTT assay absorbance readings for increasing wild type (W.T.) MLL-AF9 and
MLL(C1188A)-AF9 cell number as a function of cell viability.
(B) Experimental design for treating cells and measuring cell viability.
Relative cell viability of W.T. MLL-AF9 or MLL(C1188A)-AF9 transduced cells
following treatment with (C) hydrogen peroxide, (D) parthenolide, (E) or spermine
nonoate. Cell viability data is set relative to the untreated cell viability of MLL-AF9
or MLL(C1188A)-AF9 transduced cells, respectively (Mean ± 1 S.D.).

84
values depending whether cells would exhibit increased or decreased proliferation during
the treatments. The MTT results are presented as cell viability relative to untreated cells
transduced with wild type MLL-AF9 or mutant MLL(C1188A)-AF9.
Cells transduced with wild type (w.t.) MLL-AF9 or MLL(C1188A)-AF9 were
treated with increasing amounts of hydrogen peroxide (0-14mM), parthenolide (0-10µM),
or spermine nonoate (0-729µM). (The ranges of doses used were based on those reported
for other studies in the literature161-167.) Cells were incubated with the compounds in
culture medium for 18 hours followed by MTT assay measurement (Figure 17B).
Treatment with all reagents showed a dose-dependent decrease in viable cell
numbers in both transformed cell types (Figure 17C-E). The effects of hydrogen
peroxide and spermine nonoate on cell viability were similar for both the wild type and
the mutant C1188A cells at all doses. This was also true at higher doses of parthenolide
treatment (5-10µM). Lower doses of parthenolide (1-4µM) showed a greater decrease in
cell viability of the mutant C1188A cells compared to the wild type cells. This was
contrary to my initial hypothesis and suggest that a more sensitive assay would be
necessary to investigate the potential functional effects of oxidation or nitrosylation on
Cys1188.
Next, I performed a methylcellulose colony assay as an independent method for
measuring the longer-term effects on transformation capacity of these cells following
treatment. The same thiol-modifying agents from above were used to determine if any
selective effect on self-renewal or proliferation could be observed. Either wild type
MLL-AF9 or mutant MLL(C1188A)-AF9 transduced cells were treated as before for 18
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hours in liquid culture with increasing doses of hydrogen peroxide (0-200µM),
parthenolide (0-5µM), or spermine nonoate (0-32µM). After incubation, cells and culture
media containing the compounds were plated in semi-solid methylcellulose. Cells were
incubated for five days and colony and cell numbers were then quantified and compared
(Figure 18A). As with the MTT assay, hydrogen peroxide, parthenolide, and spermine
nonoate treatments showed dose-dependent effects on both the wild type and mutanttransduced cells with increasing doses showing fewer numbers of colonies and cells
(Figure 18B-D). Parthenolide treatment also showed dose-dependent toxicities for both
cell types. In this longer-term assay, a modest decrease in colony and cell numbers was
observed in the wild type MLL-AF9 transduced cells compared to the mutant
MLL(C1188A)-AF9 transduced cells at intermediate doses of parthenolide (1.5 and
2.5µM) (Figure 18C, note asterisks). At these intermediate doses of parthenolide, the
self-renewal and cell proliferation capacities of wild type MLL-AF9 transduced cells
were more susceptible to parthenolide treatment than the mutant MLL(C1188A)-AF9
cells. This result suggests that the cysteine 1188 residue may have a functional role in
contributing to the colony forming ability of MLL fusion proteins since the only
difference between these two cell types is a cysteine versus alanine at this position within
the CXXC domain. It is possible that Cys1188 is modified by intermediate doses of
parthenolide in a way that alters CXXC DNA-binding affinity ultimately prevents
cellular immortalization.
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Figure 18. Effect of thiol modifying agents on self-renewal and
proliferation of MLL-AF9 versus MLL(C1188A)-AF9
transformed cells.
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(A) Experimental schematic for treating wild type (W.T.) MLL-AF9 or
MLL(C1188A)-AF9 cells with thiol-modifying agents.
Dose-dependent effects of (B) hydrogen peroxide, (C) parthenolide, or (D) spermine
nonoate treatment on colony forming ability—measured as colony forming units,
CFUs—(left) and cellular proliferation (right). Results represent the averages of three
independent experiments and are set relative to the CFUs or cell numbers for
untreated MLL-AF9 or MLL(C1188A)-AF9 transduced cells, respectively.
(Mean ± 1 S.D., p-values determined by Student’s T-Test)
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Growth of MLL-AF9 and MLL(C1188A)-AF9 transduced cells under conditions of
varying oxygen concentration
The modest effects on the colony forming ability of MLL-AF9 transduced cells
compared to those transduced with MLL(C1188A)-AF9 following parthenolide treatment
suggested that the cysteine 1188 residue of MLL’s CXXC domain may be susceptible to
oxidation by parthenolide’s induction ROS which could oxidize the thiol side chain of
Cys1188 to abrogate DNA-binding and decrease colony forming potential. To further
test whether potential oxidation of cysteine 1188 could alter transformation capacity, the
MLL-AF9 and MLL(C1188A)-AF9 transformed cells were grown under conditions of
varying oxygen concentration. I hypothesized that lower oxygen concentrations (1-5%
O2) would mimic the hypoxic bone marrow niche in which hematopoietic stem and
progenitor cells reside. In this environment, cells undergo less aerobic respiration
resulting in fewer metabolic ROS which could potentially oxidize the free thiol group of
Cys1188. In contrast, the higher experimental concentrations of oxygen (21-60% O2)
would expose the wild type MLL-AF9 and mutant MLL(C1188A)-AF9 cells to higher
levels of ROS, in turn, inducing the potential oxidation of Cysteine 1188 (reversible or
irreversible) and alter the transformation capacity of the oncogenic MLL fusion protein
through altered DNA-binding affinity. I hypothesized that a hypoxic environment like
the bone marrow niche would maintain the free thiol side group of Cys1188 in a reduced
state allowing the MLL CXXC domain to bind to DNA while an environment with
increased oxygen would increase the potential for thiol oxidation of Cys1188 leading to
disruption of DNA-binding and ultimately decreasing the transforming ability of the
MLL-AF9 fusion protein.
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At all concentrations of oxygen (1-60% O2), the control MLL(C1188A)-AF9 cells
showed a lower number of colonies compared to the wild type MLL-AF9 cells (Figure
19A). This finding corresponded with the initial cell titration of this Aim 2 in which the
wild type MLL-AF9 transduced cells showed greater MTT activity (i.e. indicating a
greater overall cell viability and/or greater metabolic activity) than the mutant
MLL(C1188A)-AF9 transduced cells (Figure 17A). In order to account for this inherent
difference, the colony forming units (CFUs) were normalized to growth under room air
(21% O2) conditions (Figure 19B). This normalized data revealed only slight fluctuations
in colony forming ability from 1 to 21% O2 with no statistically significant difference
between the wild type and mutant cells. Both transformed cell types showed a marked
decrease in numbers and sizes of colonies under conditions of 60% O2 demonstrating that
both cell types are sensitive to hyperoxia, though, the effects were not more pronounced
for the wild type MLL-AF9 cells compared to the control MLL(C1188A)-AF9 cells as I
had predicted. Given that the treatment of MLL-AF9 transduced cells with thiol
modifying agents and growth under varying oxygen concentrations generated only
modest results, more sensitive experiments will need to be conducted in the future to
ultimately determine whether Cys1188 of MLL may be subject to redox regulation which
would allow this residue to function as a molecular switch that modulates DNA-binding
affinity of the CXXC domain.
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Figure 19. Effects of varying oxygen concentration on colony
forming ability of MLL-AF9 versus MLL(C1188A)-AF9
transformed cells.
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(A) Effects of varying oxygen concentration on colony forming ability—
measured as colony forming units, CFUs—of wild type MLL-AF9 or
MLL(C1188A)-AF9 cells.
(B) Colony forming ability (measured as CFUs) set relative to CFUs under 21%
oxygen concentration for each respective cell type: W.T. MLL-AF9 and
MLL(C1188A)-AF9.
Data represent averages from two to eight independent experiments (Mean ± 1
S.D.); p-values were determined by Student’s T-test comparing CFUs of W.T.
MLL-AF9 to MLL(C1188A)-AF9 at each oxygen level (*,**,***) or comparing
CFUs of 21% oxygen to CFUs at other oxygen levels (+,++,+++).

CHAPTER 5
DISCUSSION
Through a complex set of interactions involving DNA, histones, and other
transcription factors, MLL fusion proteins participate in the epigenetic misregulation of
HOX genes in leukemias with rearrangements of the MLL gene. The N-terminal portion
of MLL—including the CXXC domain and ‘post-CXXC’ residues—is essential for the
immortalizing capabilities of MLL fusions. It is not completely understood, though,
which specific residues within the CXXC domain of MLL are necessary for
leukemogenesis, nor how they mediate this function. The goal of my dissertation project
was to identify critical amino acids of the MLL CXXC domain in the context of MLL
fusion protein-mediated cell immortalization. From my studies, we could gain a better
understanding of the mechanism by which MLL causes leukemia and ultimately identify
residues which could be targeted by future therapies for MLL associated leukemias.
I used MLL2, the closest homolog of MLL, as a model to identify functionally
critical residues of the CXXC domain within the context of the well-characterized MLLAF9 fusion protein. Interestingly, MLL2 has not been found in chromosomal
translocations associated with leukemia, and the N-terminus of MLL2 cannot
functionally substitute for MLL in cell immortalization assays7. To study differences
between the specific residues of the MLL and MLL2 CXXC domains, I first generated a
fusion protein in which the MLL2 CXXC domain was swapped into MLL-AF9 to
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generate a synthetic MLL/MLL2(CXXC)-AF9 fusion protein. This chimeric fusion
protein—in which only the CXXC domains of MLL and MLL2 were exchanged—was
still capable of transforming primary hematopoietic cells. This finding suggested that
there is enough homology between these two domains that the MLL and MLL2 CXXC
domain can functionally substitute for one another and that there are likely other critical
residues outside of MLL’s CXXC domain that are able to compensate for amino acid
differences introduced by the MLL2 CXXC domain. The MLL and MLL2 CXXC
domains share about 60% homology including the highly conserved zinc-coordinating
cysteine residues found in the MLL CXXC domain that are essential for the proper
folding and stability of the domain143. Even with this degree of homology, though,
differences in DNA-binding affinity have been observed by our collaborators at the
University of Virginia. The isolated MLL2 CXXC domain shows nearly a four-fold
decrease in binding affinity for the same non-methylated CpG dinucleotides as the
isolated MLL CXXC domain (Table 6, Bushweller Lab, unpublished data) suggesting
that the amino acid differences between the MLL and MLL2 CXXC domains have
functional significance.
In order to more effectively study the role of these potentially critical residues
within MLL’s CXXC domain, additional amino acids comprising the ‘post-CXXC’
region of MLL2 were introduced into the chimeric MLL/MLL2-AF9 fusion protein along
with MLL2’s CXXC domain. The amino acid sequence of the MLL2 ‘post-CXXC’
region aligns with the ‘post-CXXC’ residues of MLL which constitute the repression
domain which our lab has previously shown binds to co-repressor proteins HDAC1,
CtBP, HPC2, and BMI-1. More recently, it was determined that the MLL CXXC and

post-CXXC domain could also interact with the PAF coactivator complex

9, 10
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. With only

about 30% homology between MLL and MLL2 in this larger region, it was possible to
reduce transformation ability by removing even more MLL residues and was perhaps also
likely to alter the functional binding of co-repressor or co-activator proteins that could
ultimately contribute to the differential leukemogenic potential of the fusion protein. The
transformation capacity of this MLL/MLL2-AF9 fusion protein was now significantly
reduced by nearly seven-fold compared to that of MLL-AF9. Using this wild type
chimeric protein, which showed only limited transformation capacity in vitro, I now had
a baseline from which I could attempt to restore colony forming ability and cellular
proliferation through the introduction of individual residues of MLL.
Thirteen amino acid substitutions were introduced into the CXXC domain of the
synthetic MLL/MLL2-AF9 fusion which restored the residues to the MLL sequence. In
vitro colony assay results showed variable capacities of these residues to rescue colony
formation and cellular proliferation compared to MLL-AF9. There was a positive
correlation between the ability of a point mutation to restore cellular transformation and
to rescue the level of Hoxa9 expression: Those constructs that generated more colonies
and cell numbers by the third round of plating in vitro also exhibited higher levels of
Hoxa9 expression after only one round of plating in vitro. The relationship between the
functional transformation data and the structure of the CXXC domain is shown in Figure
20. The residues in Figure 20 are colored according to their ability to restore (in part or
in whole) leukemogenic capacity of the chimeric fusion protein. Residue substitutions
that were able to restore function are located on both the DNA-contact surface of the
CXXC domain and on the opposite, non-DNA contacting surface. The residue
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Figure 20. Structure-function relationship between residues of the
CXXC domain
A
MLL aa1147 KKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQNLQWMPSK aa1203
MLL2 aa958 GKKMRMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARKME aa1014
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(A) Sequence alignment of the MLL and MLL2 CXXC domain highlighting the
substituted residues by their ability to rescue Hoxa9 expression levels within the
context of the MLL/MLL2-AF9 fusion protein.
(B) The MLL CXXC domain in four orientations showing amino acids as a spacefilled model and colored according to the ability of the residue(s) to rescue Hoxa9
expression levels within the MLL/MLL2-AF9 fusion protein. (DNA is shown as a
ball-and-stick model.)
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substitutions on the DNA-contact surface (i.e. A964R, P993R, T995I, V1001K, VY10012KM) could play a direct role in altering DNA-binding affinity. In contrast, those
residues showing altered function that are on the opposite surface (i.e. R970P and
LRVQ973-6QVPE) could play an indirect role on DNA-binding affinity through
allosteric effects by altering the conformation of the domain or could potentially alter
interactions with other proteins through changes in conformation or surface charges.
In vitro binding studies were conducted to see if any of these amino acid
substitutions within the CXXC domain could alter DNA binding or binding to other
cofactor proteins previously shown to interact with the MLL repression domain.
Aravinda Kuntimaddi (from the Bushweller laboratory at the University of Virginia)
performed preliminary studies on isolated CXXC domain to test DNA-binding affinity
(Table 6). The A964R substitution within the MLL2 CXXC domain was able to almost
completely restore DNA binding affinity to the level of MLL. This finding along with
the functional colony assay data with this substitution confirms the importance of CXXC
domain binding to DNA that was previously shown by our labs11. In the NMR solution
structure of the MLL CXXC domain complexed with DNA, this residue (arginine 1153 in
MLL) was not shown to form a direct interaction with the DNA. The flanking residues,
however, both contact the phosphate backbone so R1153 of MLL may help to stabilize
these interactions to increase DNA-binding affinity11.
Table 6. DNA binding affinities of isolated wild type and mutant CXXC domains.
CXXC Domain Kd (µM)
wt MLL
90
wt MLL2
340
A964R MLL2
96
R1011M MLL2
170
Data provided by Aravinda Kuntimaddi & John Bushweller, PhD (University of Virginia)
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The DNA binding affinity of the R1011M MLL2 CXXC mutant was also
determined by the Bushweller lab. This substitution showed a fifty percent restoration of
DNA binding affinity, yet in contrast to the A964R substitution, this partial increase in
affinity did not manifest in a rescue of transformation capacity. In fact, the R1011M
substitution showed no increase in colony forming ability and a decrease in Hoxa9
expression compared to the wild type fusion protein. This finding suggests that there
may be a minimum DNA-binding affinity of the CXXC domain necessary for conferring
the capacity for transformation to the fusion proteins. Additional DNA-binding studies
will need to be performed to determine if altered DNA binding accounts for the
functional rescue observed for any of the other residue substitutions (i.e. R970P,
LRVQ973-6QVPE, or V1001K). I hypothesizethat the V1001K substitution, in
particular, could increase DNA-binding affinity, as the lysine residue in this position
(K1190 of MLL) was previously shown to form an electrostatic interaction with the
phosphate backbone of DNA11. Reintroducing the positively charged side group of
lysine in this position would likely enhance the ability of the MLL2 CXXC domain to
bind to DNA and account for the partial functional restoration of both the V1001K and
the VY1001-2KM substitutions.
I performed in vitro binding studies between co-repressors or PAF1 and the
isolated wild type or mutant repression domains using a subset of the constructs from the
functional colony assay studies. The three constructs showing the greatest rescue of
function (colony formation, cell proliferation, and Hoxa9 expression) were chosen—
A964R, R970P, and LRVQ973-6QVPE—along with a substitution showing intermediate
restorative effects (V1001K). The R1011M substitution was also studied for comparison
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to the wild type MLL1/2 repression domain since this mutant construct showed equally
low transformation capacity as the wild type MLL/MLL2-AF9 fusion protein in the
methylcellulose colony assay.
The MLL repression domain showed similar binding to co-repressors HDAC1
and CtBP compared to the chimeric MLL1/2 repression domain containing ‘pre-CXXC’
residues from MLL and residues from MLL2 comprising the CXXC domain and ‘postCXXC’ region. This construct was the equivalent “repression domain” present in the
fusion constructs used in the colony assay and was cloned for this in vitro binding study
so that I could determine whether altered co-repressor binding could account for
differences in any of the functional data observed with the studied chimeric fusions.
Each of the five amino acid substitutions that were tested showed relatively similar
amount of binding to HDAC1 and CtBP compared to wild type MLL or MLL1/2
repression domain constructs. The minimal reduction in HDAC1 binding that was
observed for the R970P construct compared to the MLL1/2 construct (p > 0.05) cannot
alone account for the observed functional changes in the colony assay, however, because
the R1011M construct (which showed no functional rescue) also exhibited a slight
decrease in HDAC1 binding, though, the differences in binding were not statistically
significant (p > 0.05). Likewise, the increased CtBP binding by V1001K was
comparable to the increase observed with the R1011M mutant protein.
The in vitro binding studies using the repression domain constructs showed
enhanced binding of HPC2 to the MLL1/2 repression domain compared to the MLL
repression domain. The wild type MLL1/2 construct showed at least a two-fold increase
in binding to HPC2 compared to the MLL repression domain; however, when the results
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of multiple experiments were averaged together, this binding difference did not achieve
statistical significance due to the dynamic range of the band intensities between
experiments. The amino acid substitutions observed in the binding studies (A964R,
R970P, LRVQ973-6QVPE, V1001K, and R1011M) showed no difference (p > 0.05) in
binding when compared to the MLL1/2 repression domain. This finding suggests that
HPC2 binding does not account for the functional differences observed for the fusion
proteins that were studied in the in vitro transformation assay. Future interaction studies
between MLL and other cofactor proteins will need to be performed to account for any
functional differences between the mutant constructs which are not explained solely by
differences in DNA-binding affinity. Our laboratory has previously shown that the
polycomb group protein BMI-1 also interacts with the MLL repression domain8.
Differential binding of BMI-1 to the mutant repression domain constructs has yet to be
explored and could potentially explain the functional differences observed for some of
the mutant MLL/MLL2-AF9 constructs. Screening for other proteins which interact with
the MLL repression domain may also yield additional candidates for future in vitro
binding studies.
Recent studies have implicated a role for the polymerase associated factor
complex (PAFc) in MLL leukemia9, 10. MLL directly interacts with PAFc through an
interaction with the PAF1 subunit in the regions flanking the CXXC domain. Sequential
deletion studies determined the minimal interaction domain to include residues of the
MLL ‘pre-CXXC’ (residues 1115-1154) and the MLL ‘post-CXXC’ (residues 12091299) region which together are found within the repression domain of MLL
(functionally defined as MLL residues 1100-1400)3, 10. PAFc interacts with the MLL-
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AF9 fusion protein to help in the recruitment of the fusion and to enhance Hoxa9
expression. Mutation and deletion studies showed that loss of the PAFc interaction
prevented recruitment of MLL or MLL fusions to target gene promoters and for
transformation in vitro9, 10.
My in vitro binding studies confirmed that the MLL repression domain directly
interacts with the PAF1 protein subunit of PAFc. Using the chimeric MLL1/2 repression
domain construct made up of the analogous repression domain from the minimally
transforming fusion protein, I found that PAF1 is able to bind directly in equal amounts
compared to the MLL repression domain. It was previously shown that a region of
MLL2 comprised of the residues flanking the CXXC domain was unable to bind to PAF1
(presumably residues 900 to roughly 1042 of MLL2; the actual residues are not reported
in the publication)9. The difference in findings might be attributed to the ‘pre-CXXC’
residues which, in my construct, are from MLL and were shown by Muntean et al. to be
essential for binding PAF1 or perhaps also attributed to the extended ‘post-CXXC’
residues from MLL2 in my constructs which would align with the full repression domain
from MLL10. The structure and function of the MLL and MLL2 ‘post-CXXC’ regions
have yet to be determined. Future studies will be necessary to understand the specific
role of this region in normal MLL function and in the functioning of leukemogenic fusion
proteins.
Of particular interest is a R1153A mutation (R1153 of MLL mutated to alanine)
studied by Milne et al. in an interaction between PAF1 and a mutant MLL construct
comprised of the first half of the MLL repression domain (MLL residues 1101-1250)9.
This is the exact opposite mutation which I had generated within the MLL2 CXXC
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domain—A964R—in which an alanine is present in this position in MLL2 and an
arginine in MLL. The authors show that introducing this single R1153A mutation into
MLL disrupts the interaction of PAF1 even when critical residues flanking the MLL
CXXC domain are still present as were shown to be necessary for interaction with PAF1
by Muntean et al9, 10. At the same time, the authors speculate that this mutation does not
alter DNA-binding affinity based on the findings of an electrophoretic mobility shift
assay (EMSA) using the MLL2 CXXC domain which has an alanine in this position7. In
contrast to this hypothesis, though, our collaborators have now shown through a
quantitative method (NMR titration) that an alanine residue in this position of the CXXC
domain does indeed alter DNA binding affinity (Table 6) and the reverse mutation in the
MLL2 CXXC domain (A964R) nearly completely restores DNA affinity levels to that of
the MLL CXXC domain.
When individual amino acid substitutions from MLL were introduced into the
MLL1/2 repression domain, I observed no altered PAF1 binding for any of the isolated
GST-tagged constructs (p > 0.05). The absence of a change in binding is likely due to the
equal binding of PAF1 to both the wild type MLL and the wild type MLL1/2 repression
domains so that introduction of MLL residues into the MLL1/2 construct would not
enhance or disrupt binding to any great extent. This finding of unaltered PAF1 binding
between the wild type MLL and MLL1/2 repression domains and the mutant repression
domains is significant given the previous findings that PAF1 recruitment is necessary for
leukemogenesis. This finding demonstrates that the PAF1 interaction with MLL—while
it may be necessary—is not sufficient to confer a transforming capacity to an MLL fusion
protein.
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Furthermore, the findings of PAF1 binding to all repression domain constructs
along with the in vitro DNA-binding data of our collaborators help to distinguish the
importance of PAF complex recruitment from the ability of MLL to bind to its nonmethylated DNA targets. The wild type MLL and MLL1/2 repression domain constructs
are both able to bind to PAF1, suggesting that the PAF complex would be subsequently
recruited to target loci. However, my functional colony assay data showed differences in
transformation abilities of the MLL-AF9 and MLL/MLL2-AF9 fusion proteins as the
latter formed only minimal colonies comprised of differentiated cells. Significantly, the
MLL/MLL2-AF9 transduced bone marrow cells showed only minimal increase in Hoxa9
expression levels compared to the negative control even though PAF1 is able to bind to
the chimeric repression domain and would be expected to enhance gene transcription
through recruitment of PAFc, as reported previously. There were significant differences
observed in DNA-binding affinities, however, between the wild type MLL and MLL2
CXXC domains and the A964R CXXC domain. The A964R mutation nearly restored
DNA binding affinity while showing no alteration of PAF1 binding to the repression
domain construct in vitro (i.e. no increased binding to PAF1 as might have been expected
with this reverse mutation according to the previous report by Milne et al9) demonstrating
that DNA binding of the CXXC domain mediated by the MLL R1153 residue is of
paramount importance for leukemogenesis and recruitment of PAFc may be a subsequent
step in the process of transformation. A chromatin immunoprecipitation experiment
looking at co-recruitment of PAF and the fusion protein to the Hoxa9 promoter would
further substantiate this conclusion.
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Table 7. Summary of functional in vitro transformation and DNA-binding data.
MLL
MLL1/2
A964R
H968Q
R970P
V975P
LRVQ973-6QVPE
V982T
P993R
T995I
V1001K
VY1001-2KM
R1011M

Cell
Transformation
++++
+
++
+
+++
+
++
+
++
++
++
++
+

Hoxa9
Expression
++++
+
++++
++
+++
++
++++
+
++
++
+++
+++
-

DNA
binding
+++
+
+++
ND
ND
ND
ND
ND
ND
ND
ND
ND
++

Symbols indicate approximate 2-3 fold (++), 4-5 fold
(+++), or >5 fold (++++) increase in functional activity
compared to baseline MLL1/2 levels (+), a relative
reduction (-) in activity compared to MLL1/2, or data not
determined (ND)
A summary of the results from my studies comparing residues of the MLL and
MLL2 CXXC domains are shown Table 7. Taken together, the results suggest a model
whereby specific residues on both the inner DNA-contact surface and on the opposite,
non-DNA-contact surface of the MLL CXXC domain (i.e. R1153 and QVPE1162-5 of
MLL) are critical for the transformation capacity of an MLL fusion protein (Figure 21).
The arginine 1153 residue of MLL has now been determined by our collaborators to
increase DNA-binding affinity when introduced into the MLL2 CXXC domain (A964R
substitution). In contrast to the MLL, the CXXC domain of MLL2 shows a lower affinity
for non-methylated DNA. This difference can be attributed to the absence of a positive
charge at this position in MLL2 (A964 of MLL2 versus R1153 of MLL) which could
form an electrostatic interaction with the negatively charged phosphate backbone of the
DNA to enhance binding. The role of the critical residues on the outer CXXC domain
surface (i.e. P1159 and QVPE1162-5 of MLL) has yet to be determined as these residues
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Figure 21. Models of the MLL and MLL2 CXXC domains showing
differential DNA binding and equivalent binding to
cofactor proteins.
A

MLL CXXC

HDAC1

CtBP
HPC2
PAF1
B MLL2 CXXC

HDAC1

CtBP
HPC2
PAF1
(A) Model of the MLL CXXC domain (green space-filling model) showing binding
with high affinity to DNA (ball-and-stick model) dependent on R1153 of MLL (A964
in MLL2).
(B) Model of MLL2 CXXC domain (blue space-filling model) showing weaker
binding to DNA (ball-and-stick model) through A964 of MLL2 (R1153 in MLL).
(Note that both CXXC domains show similar binding to cofactor proteins HDAC1,
HPC2, CtBP, and PAF1. A patch of 4 residues (MLL QVPE1162-1165 and MLL2
LRVQ973-6) which showed high functional restoration of colony forming ability and
Hoxa9 expression are highlighted in red on the opposite, non-DNA contact surface.)
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did not significantly alter binding of cofactor proteins (HDAC1, HPC2, CtBP, and PAF1)
in a way that corresponded to the observed transformation capacities. It is possible that
DNA-binding studies of the isolated domains may reveal that residue differences on the
outer surface may have an impact on DNA binding affinity perhaps through allosteric
changes within the CXXC domain. In both models of Figure 21, it is the ability of the
CXXC domain to bind to DNA that allows for the recruited PAF complex to enhance
transcription of target genes and ultimately contribute to leukemogenesis.
The second aim of my dissertation focused on the role of MLL’s Cys1188, the
only non-zinc coordinating cysteine residue within the CXXC domain. This residue is
conserved in the CXXC domains of vertebrate MLL orthologs and also in the MLL2
CXXC domain. The proliferation and colony forming ability of MLL-AF9 transduced
cells was measured following treatment with various thiol modifying agents. MTT
assays and colony formation assays showed dose-dependent toxicities of MLL-AF9 (and
control MLL(C1188A)-AF9) cells treated with hydrogen peroxide, parthenolide, and
spermine nonoate.
Hydrogen peroxide is a strong oxidizing agent capable of undergoing the Fenton
reaction in which reactive oxygen species are generated. These free radicals can, in turn,
oxidize free thiol groups in a reversible (i.e. induction of disulfide bond formation) or an
irreversible (i.e. sulfonic acid formation) manner. Several reports have shown that
growth factor stimulation of hematopoietic cells induces the production of intermediate
levels of reactive oxygen species (ROS) that activate signaling pathways to mediate cell
cycle progression implicating a role for ROS in normal hematopoiesis and leukemia
development161, 162, 168. However, at higher levels like those observed with treatment of
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high concentrations of hydrogen peroxide, ROS is damaging to DNA, proteins, and lipids
causing an induction of apoptosis. Increases in programmed cell death at high levels of
hydrogen peroxide treatment likely accounted for the decreased proliferation and colony
forming ability of both the MLL-AF9 and control MLL(C1188A)-AF9 cells in the MTT
and colony formation assays.
Parthenolide is a sesquiterpene lactone derived from the feverfew plant
(Tanacetum parthenium) which has been used for aboriginal medicinal purposes ranging
from treatment of headaches to inflammatory disorders169. The lactone ring and epoxide
group of parthenolide are susceptible to nucleophilic attack by reactive side chains
including sulfydryl groups. Parthenolide has recently gained interest as an anti-cancer
compound for its ability to induce formation of intracellular reactive oxygen species and
mediate apoptosis through oxidative stress163, 170, 171. This increase in ROS could then
cause oxidation of free thiol groups like Cys1188 of the MLL CXXC domain and
potentially interfere with DNA binding. Interestingly, parthenolide has also been shown
to decrease DNA methylation by DNA methyltransferase 1 (DNMT1) through alkylation
of a free thiol side group within the catalytic site172. It is possible that parthenolide could
form a similar covalent adduct to MLL’s Cys1188 through a Michael’s reaction which
would sterically interfere with the binding of the CXXC domain to its non-methylated
DNA targets.
The MTT assays and colony forming assays showed dose-depdendent toxicities of
parthenolide on MLL-AF9 and the control MLL(C1188A)-AF9 cells. Unlike hydrogen
peroxide and spermine nonoate, however, the MLL-AF9 cells showed a modest
sensitivity to parthenolide treatment compared to the mutant control cells at intermediate
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treatment concentrations. Since the only difference in these cell lines is the Cys1188
residue, it can be concluded that this non-zinc-coordinating cysteine residue has a minor
effect on cell proliferation and colony formation in the context of the in vitro colony
assay. The modest affect of parthenolide on Cys1188 of the MLL CXXC domain may be
associated with the indirect increase of intracellular ROS or with a direct binding of the
lactone ring to the thiol side group. The exact mechanism for this effect was not
determined in my colony assay studies. It would be possible to determine if a covalent
parthenolide adduct is present through tandem mass spectrometry in which the MLL-AF9
fusion protein could be purified from a large number of treated cells using the fusion
protein’s FLAG tag. If a spectral shift corresponding to parthenolide’s molecular weight
is observed compared to untreated MLL-AF9 protein, it can be concluded that
parthenolide covalently modifies Cys1188 to perturb the transformation capacity of
MLL-AF9 cells. In contrast, the lack of a spectral shift from treated MLL-AF9 protein
might indicate that the generation of ROS could reversibly oxidize Cys1188 to alter
fusion protein function. An in vitro DNA-binding study could also be performed to
determine the direct DNA-binding effects of parthenolide treatment on the isolated MLL
CXXC domain. Ultimately, the toxicity of parthenolide on MLL-AF9 cells is likely
mediated through programmed cell death pathways as previously reported for many
AML cell types165.
Treatment of MLL-AF9 and control cells with spermine nonoate showed dosedependent cellular toxicities for both cell lines and, like hydrogen peroxide treatment, no
significant differences in effects were observed between proliferation and colony
formation of the either cell type. Spermine nonoate is a nitric oxide (NO) donor that has

106
previously been shown to have anti-proliferative effects on tumor cells through inhibition
of cell cycle progression and induction of cellular necrosis166, 167. Treatment of MLLAF9 wild type and mutant cell lines did not show differential sensitivities to spermine
nonoate treatment which was equally toxic at high concentrations. While moderate
amounts of NO are known to stimulate the mobilization of hematopoietic cells, higher
levels of NO appear to be cytotoxic to leukemia cells in the in vitro MTT and colony
assays45.
The treatment of MLL-AF9 cells with thiol modifying agents and growth of these
cells under varying oxygen levels yielded only modest results. It still remains to be more
clearly determined whether Cys1188 is susceptible to redox regulation that would allow
this residue to function as a molecular switch to modulate binding of the CXXC domain
to DNA. Treatment of cells with a wider array of oxidizing agents may confirm the
modest effects observed by parthenolide, though, a more sensitive assay would be useful
for determining altered effects on Cys1188 as global treatment effects (i.e. oxidation of
free thiol groups throughout the cell and induction of oxidative stress) may have masked
the specific effects of an individual cysteine residue. An in vitro DNA-binding study in
which the isolated CXXC domain is treated with possible modifying agents could
measure the direct DNA-binding effects of any potential Cys1188 changes. In addition,
tandem mass spectrometry could be used to screen for possible modifications of Cys1188
from purified MLL-AF9 fusion proteins. Any spectral shifts associated with the Cys1188
residue could be evaluated to determine what modification(s) may be present at this
particular position. If and when it is definitively determined how potential Cys1188
modifications can alter the function of the CXXC domain, the susceptible side chain of
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Cys1188 could be targeted with therapies to alter functions of the leukemogenic MLL
fusion protein.
Ultimately, the CXXC domain of MLL may be an ideal target for future therapies
for MLL-associated leukemias. The requirement of this domain for transformation of
hematopoietic cells suggests that disruption of critical interactions within this domain
would offer some hope for patients. By comparing the residues of the MLL and MLL2
CXXC domains, critical amino acids were identified on both the DNA contact surface
and the opposite, non-DNA contact surface that contribute to leukemogenic capacity.
Small molecule inhibitors against the DNA-binding surface of the MLL CXXC domain
would be particularly effective if the target includes the critical R1153 residue leading to
disruption of DNA binding. In addition, leukemia treatments that target the hypoxic bone
marrow niche may also selectively target the leukemic stem cell populations that give rise
to the burden of leukemia cells and subsequent relapse of disease. Currently, the
therapies for MLL-associated leukemia are limited, resulting in poor clinical outcomes.
Knowledge of specific residues within the MLL CXXC domain which are critical to the
leukemogenic capacity of MLL fusions may offer improved strategies for treating these
aggressive forms of leukemia.
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